

### 3. DOSIMETRY OF DIESEL PARTICULATE MATTER

#### 3.1. INTRODUCTION

Clearly, animals and humans receive different internal doses when breathing the same external concentrations of airborne materials such as diesel particulate matter (DPM) (Brain and Mensah, 1983; Schlesinger, 1985). The dose received in different species differs from the aspects of the total amount deposited within the respiratory tract, the relative distribution of the dose to specific regions in the respiratory tract, and the residence time of these materials within the respiratory tract, i.e., clearance. Using an external concentration breathed by laboratory animals as a basis for any guidance for human exposure to DPM would then be an inadequate approximation of the total and regional dose that humans may receive. The objective of this chapter is to evaluate and address this issue of interspecies dosimetric differences through:

- A general overview of what is known about how particles like DPM are deposited, transported to, and cleared from the respiratory tract. Information on both laboratory animals (mainly rodents) and humans will be considered and interspecies similarities and differences highlighted.
- An overview of what is known about the bioavailability of the organic compounds adsorbed onto DPM from information in humans, animals, and in vitro studies, and from model predictions.
- An evaluation of the suitability of available dosimetric models and procedures for DPM to perform interspecies extrapolations whereby an exposure scenario, conditions, and outcome in laboratory animals are adjusted to an equivalent outcome in humans via calculation of an internal dose.

The focus in this chapter will be on the particulate fraction of diesel emissions, i.e., DPM. Although diesel engine exhaust consists of a complex mixture of typical combustion gases, vapors, low-molecular-weight hydrocarbons, and particles, it is the particle phase that is considered to be of major health concern. The major constituents of diesel exhaust and their atmospheric reaction products are described here (Chapter 2).

As will be deduced in Chapter 5, pulmonary toxicity and carcinogenicity is the major focal point of diesel toxicity and of DPM deposition. Therefore, dosimetric considerations are limited to the lung. Aspects of respiratory tract dosimetry to be considered in this chapter include the characteristics of DPM, deposition of DPM in the conducting airways and alveolar regions, normal DPM clearance mechanisms and rates of clearance in both these regions, clearance rates

1 during lung overload (in rats), elution of organics from DPM, transport of DPM to extra-alveolar  
2 sites, and the interrelationships of these factors.

3 The overall goal in this chapter follows from the objective—to judge the feasibility and  
4 suitability of procedures allowing for derivation of an internal dose estimate of DPM for humans,  
5 i.e., of a human equivalent concentration to exposure concentrations and conditions used in  
6 animal studies. This goal is of significance especially in the quantitative dose-response analysis of  
7 DPM effects proposed in Chapter 6.

### 8 9 **3.2. CHARACTERISTICS OF INHALED DPM**

10 The formation, transport, and characteristics of DPM are considered in detail in Chapter 2.  
11 DPM consists of aggregates of spherical carbonaceous particles (typically about 0.2  $\mu\text{m}$  mass  
12 median aerodynamic diameter [MMAD]) to which significant amounts of higher-molecular-weight  
13 organic compounds are adsorbed. DPM has an extremely large surface area that allows for the  
14 adsorption of organic compounds. The organic carbon portion of DPM can range from at least  
15 19% to 43% from highway diesel engines; no data are available to characterize the organic  
16 content of DPM from nonroad engines. The toxicologically relevant organic chemicals include  
17 high-molecular-weight hydrocarbons such as the polycyclic aromatic hydrocarbons (PAHs) and  
18 their derivatives (Section 2.2.8).

### 19 20 **3.3. REGIONAL DEPOSITION OF INHALED DPM**

21 This section discusses the major factors controlling the disposition of inhaled particles.  
22 Note that disposition is defined as encompassing the processes of deposition, absorption,  
23 distribution, metabolism, and elimination. The regional deposition of particulate matter in the  
24 respiratory tract is dependent on the interaction of a number of factors, including respiratory tract  
25 anatomy (airway dimensions and branching configurations), ventilatory characteristics (breathing  
26 mode and rate, ventilatory volumes and capacities), physical processes (diffusion, sedimentation,  
27 impaction, and interception), and the physicochemical characteristics (particle size, shape, density,  
28 and electrostatic attraction) of the inhaled particles. Regional deposition of particulate material is  
29 usually expressed as deposition fraction of the total particles or mass inhaled and may be  
30 represented by the ratio of the particles or mass deposited in a specific region to the number or  
31 mass of particles inspired. The factors affecting deposition in these various regions and their  
32 importance in understanding the fate of inhaled DPM are discussed in the following sections.

33 It is beyond the scope of this document to present a comprehensive account of the  
34 complexities of respiratory mechanics, physiology, and toxicology, and only a brief review will be  
35 presented here. The reader is referred to publications that provide a more in-depth treatment of

1 these topics (Weibel, 1963; Brain and Mensah, 1983; Raabe et al., 1988; Stöber et al., 1993; U.S.  
2 EPA, 1996).

3 The respiratory tract in both humans and experimental mammals can be divided into three  
4 regions on the basis of structure, size, and function (International Commission on Radiological  
5 Protection, 1994): the extrathoracic (ET), the tracheobronchial (TB), and the alveolar (A). In  
6 humans, inhalation can occur through the nose or mouth or both (oronasal breathing). Many  
7 animal models used in respiratory toxicology studies are, however, obligate nose breathers.  
8

### 9 **3.3.1. Deposition Mechanisms**

10 This section provides an overview of the basic mechanisms by which inhaled particles  
11 deposit within the respiratory tract. Details concerning the aerosol physics that explain both how  
12 and why particle deposition occurs as well as data on total human respiratory tract deposition are  
13 presented in detail in the earlier PM Criteria Document (U.S. EPA, 1996) and will only be briefly  
14 summarized here. For more extensive discussions of deposition processes, refer to reviews by  
15 Morrow (1966), Raabe (1982), U.S. EPA (1982), Phalen and Oldham (1983), Lippmann and  
16 Schlesinger (1984), Raabe et al. (1988), and Stöber et al. (1993).

17 Particles may deposit by five major mechanisms (inertial impaction, gravitational settling,  
18 Brownian diffusion, electrostatic attraction, and interception). The relative contribution of each  
19 deposition mechanism to the fraction of inhaled particles deposited varies for each region of the  
20 respiratory tract.

21 It is important to appreciate that these processes are not necessarily independent but may,  
22 in some instances, interact with one another such that total deposition in the respiratory tract may  
23 be less than the calculated probabilities for deposition by the individual processes (Raabe, 1982).  
24 Depending on the particle size and mass, varying degrees of deposition may occur in the  
25 extrathoracic or ET (or nasopharyngeal), tracheobronchial (TB), and alveolar regions of the  
26 respiratory tract.

27 Upon inhalation of particulate matter such as that found in diesel exhaust, particle  
28 deposition will occur throughout the respiratory tract. Because of high airflow velocities and  
29 abrupt directional changes in the ET and TB regions, inertial impaction is a primary deposition  
30 mechanism, especially for particles  $\geq 2.5 \mu\text{m } d_{\text{ae}}$  (aerodynamic equivalent diameter). Although  
31 inertial impaction is a prominent process for deposition of larger particles in the tracheobronchial  
32 region, it is of minimal significance as a determinant of regional deposition patterns for DPM,  
33 which have a  $d_{\text{ae}} \leq 1 \mu\text{m}$ .

34 All aerosol particles are continuously influenced by gravity, but particles with a  
35  $d_{\text{ae}} > 0.5 \mu\text{m}$  are affected to the greatest extent. A spherical compact particle will acquire a  
36 terminal settling velocity when a balance is achieved between the acceleration of gravity acting on

1 the particle and the viscous resistance of the air; it is this velocity that brings the particle into  
2 contact with airway surfaces. Both sedimentation and inertial impaction cause the deposition of  
3 many particles within the same size range. These deposition processes act together in the ET and  
4 TB regions, with inertial impaction dominating in the upper airways and sedimentation becoming  
5 increasingly dominant in the lower conducting airways, especially for the largest particles that can  
6 penetrate into the smaller bronchial airways.

7 As particle diameters become  $<1 \mu\text{m}$ , the particles are increasingly subjected to diffusive  
8 deposition because of random bombardment by air molecules, which results in contact with  
9 airway surfaces. A  $d_{ae}$  of  $0.5 \mu\text{m}$  is often considered a boundary between diffusion and  
10 aerodynamic (sedimentation and impaction) mechanisms of deposition. Thus, instead of having a  
11  $d_{ae}$ , diffusive particles of different shapes can be related to the diffusivity of a thermodynamic  
12 equivalent size based on spherical particles (Heyder et al., 1986). Diffusive deposition of particles  
13 is favored in the A region of the respiratory tract as particles of this size are likely to penetrate  
14 past the ET and TB regions.

15 Electrostatic precipitation is deposition related to particle charge. The electrical charge on  
16 some particles may result in an enhanced deposition over what would be expected from size  
17 alone. This is due to image charges induced on the surface of the airway by these particles, or to  
18 space-charge effects whereby repulsion of particles containing like charges results in increased  
19 migration toward the airway wall. The effect of charge on deposition is inversely proportional to  
20 particle size and airflow rate. A recent study employing hollow airway casts of the human  
21 tracheobronchial tree that assessed deposition of ultrafine ( $0.02 \mu\text{m}$ ) and fine ( $0.125 \mu\text{m}$ ) particles  
22 found that deposition of singly charged particles was 5-6 times that of particles having no charge,  
23 and 2-3 times that of particles at Boltzmann equilibrium (Cohen et al., 1998). This suggests that  
24 within the TB region of humans, electrostatic precipitation may be a significant  
25 deposition mechanism for ultrafine and some fine particles, the latter of which are inclusive of  
26 DPM. Thus, although electrostatic precipitation is generally a minor contributor to overall  
27 particle deposition, it may be important for DPM.

28 Interception is deposition by physical contact with airway surfaces and is most important  
29 for fiber deposition (U.S. EPA, 1996).

### 30 31 **3.3.1.1. *Biological Factors Modifying Deposition***

32 The available experimental deposition data in humans are commonly derived using healthy  
33 adult Caucasian males. Various factors can act to alter deposition patterns from those obtained in  
34 this group. The effects of different biological factors, including gender, age, and respiratory tract  
35 disease, on particle deposition have been reviewed previously (U.S. EPA, 1996, Section

1 10.4.1.6). In general, there appears to be an inverse relationship between airway resistance and  
2 total deposition.

3 The various species that serve as the basis for dose-response assessment in inhalation  
4 toxicology studies do not receive identical doses in a comparable respiratory tract region (ET,  
5 TB, or A) when exposed to the same aerosol or gas (Brain and Mensah, 1983). Such interspecies  
6 differences are important because the adverse toxic effect is likely more related to the quantitative  
7 pattern of deposition within the respiratory tract than to the exposure concentration; this pattern  
8 determines not only the initial respiratory tract tissue dose but also the specific pathways by which  
9 the inhaled material is cleared and redistributed (Schlesinger, 1985). Differences in patterns of  
10 deposition between humans and animals have been summarized (U.S. EPA, 1996; Schlesinger et  
11 al., 1997). Such differences in initial deposition must be considered when relating biological  
12 responses obtained in laboratory animal studies to effects in humans.

13 The deposition of inhaled diesel particles in the respiratory tract of humans and  
14 mammalian species has been reviewed (Health Effects Institute, 1995). Schlesinger (1985)  
15 showed that physiological differences in the breathing mode for humans (nasal or oronasal  
16 breathers) and laboratory rats (obligatory nose breathers), combined with different airway  
17 geometries, resulted in significant differences in lower respiratory tract deposition for larger  
18 particles ( $>1 \mu\text{m } d_{ae}$ ). In particular, a much lower fraction of inhaled larger particles is deposited  
19 in the alveolar region of the rat compared with humans. However, relative deposition of the much  
20 smaller diesel exhaust particles was not affected as much by the differences among species, as was  
21 demonstrated in model calculations by Xu and Yu (1987). These investigators modeled the  
22 deposition efficiency of inhaled DPM in rats, hamsters, and humans on the basis of calculations of  
23 the models of Schum and Yeh (1980) and Weibel (1963). These simulations (Figure 3-1) indicate  
24 relative deposition patterns in the lower respiratory tract (trachea = generation 1; alveoli =  
25 generation 23) and are similar among hamsters, rats, and humans. Variations in alveolar  
26 deposition of DPM over one breathing cycle in these different species were predicted to be within  
27 30% of one another. Xu and Yu (1987) attributed this similarity to the fact  
28 that deposition of the submicron diesel particles is dominated by diffusion rather than  
29 sedimentation or impaction. Although these data assumed nose-breathing by humans, the results  
30 would not be very different for mouth-breathing because of the low filtering capacity of the nose  
31 for particles in the 0.1 to 0.5  $\mu\text{m}$  range.

32 For dosimetric calculations and modeling, it would be of much greater importance to  
33 consider the actual dose deposited per unit surface area of the respiratory tract rather than the  
34 relative deposition efficiencies per lung region. Table 3-1 compares the predicted deposited doses  
35 of DPM inhaled in 1 min for the three species, based on the total lung volume, the surface area of  
36 all lung airways, or the surface area of the epithelium of the alveolar region only. In Table 3-1,

1 the deposited dose, expressed as either mass/lung volume (M) or mass/surface area(s) ( $M_1$ ), or  
2 mass/alveolar surface area ( $M_2$ ) is lower in humans than in the two rodent species as a result of  
3 the greater respiratory exchange rate in rodents and smaller size of the rodent lung. Such  
4 differences in the deposited dose in relevant target areas are important and have to be considered  
5 when extrapolating the results from DPM/DE exposure studies in animals to humans. Table 3-1  
6 indicates that the differences (between humans to animals) are less on a surface area basis  
7 ( $\approx 3$ -fold) than on a lung volume basis ( $\approx 14$ -fold). This is due to larger alveolar diameters and  
8 concomitant lower surface area per unit of lung volume in humans.

9 Particle deposition will initiate particle redistribution processes (e.g., clearance  
10 mechanisms, phagocytosis) that transfer the particles to various subcompartments, including the  
11 alveolar macrophage pool, pulmonary interstitium, and lymph nodes. Over time, therefore, only  
12 small amounts of the original particle intake would be associated with the alveolar surface.

### 14 **3.3.2. Particle Clearance and Translocation Mechanisms**

15 This section provides an overview of the mechanisms and pathways by which particles are  
16 cleared from the respiratory tract. The mechanisms of particle clearance as well as clearance  
17 routes from the various regions of the respiratory tract have been considered in the PM Criteria  
18 Document (U.S. EPA, 1996) and reviewed by Schlesinger et al. (1997).

19 Particles that deposit upon airway surfaces may be cleared from the respiratory tract  
20 completely, or be translocated to other sites within this system, by various regionally distinct  
21 processes. These clearance mechanisms can be categorized as either absorptive (i.e., dissolution)  
22 or nonabsorptive (i.e., transport of intact particles) and may occur simultaneously or with  
23 temporal variations. Particle solubility in terms of clearance refers to solubility within the  
24 respiratory tract fluids and cells. Thus, a poorly soluble particle is one whose rate of clearance by  
25 dissolution is insignificant compared to its rate of clearance as an intact particle (as is the case  
26 with DPM). The same clearance mechanisms act on specific particles to different degrees, with  
27 their ultimate fate being a function of deposition site, physicochemical properties (including any  
28 toxicity), and sometimes deposited mass or number concentration.

#### 30 **3.3.2.1. Extrathoracic Region**

31 The clearance of poorly soluble particles deposited in the nasal passages occurs via  
32 mucociliary transport, and the general flow of mucus is backwards, i.e., towards the nasopharynx.  
33 Mucus flow in the most anterior portion of the nasal passages is forward, clearing deposited  
34 particles to the vestibular region where removal is by sneezing, wiping, or blowing.

35 Soluble material deposited on the nasal epithelium is accessible to underlying cells via  
36 diffusion through the mucus. Dissolved substances may be subsequently translocated into the

1 bloodstream. The nasal passages have a rich vasculature, and uptake into the blood from this  
2 region may occur rapidly.

3 Clearance of poorly soluble particles deposited in the oral passages is by coughing and  
4 expectoration or by swallowing into the gastrointestinal tract.

### 6 **3.3.2.2. Tracheobronchial Region**

7 The dynamic relationship between deposition and clearance is responsible for determining  
8 lung burden at any point in time. Clearance of poorly soluble particles from the TB region is  
9 mediated primarily by mucociliary transport, a more rapid process than those operating in alveolar  
10 regions. Mucociliary transport (often referred to as the mucociliary escalator) is accomplished by  
11 the rhythmic beating of cilia that line the respiratory tract from the trachea through the terminal  
12 bronchioles. This movement propels the mucous layer containing deposited particles (or particles  
13 within alveolar macrophages [AMs]) toward the larynx. Clearance rate by this system is  
14 determined primarily by the flow velocity of the mucus, which is greater in the proximal airways  
15 and decreases distally. These rates also exhibit interspecies and individual variability.

16 Considerable species-dependent variability in tracheobronchial clearance has been reported, with  
17 dogs generally having faster clearance rates than guinea pigs, rats, or rabbits (Felicetti et al.,  
18 1981). The half-time ( $t_{1/2}$ ) values for tracheobronchial clearance of relatively insoluble particles  
19 are usually on the order of hours, as compared to alveolar clearance, which is on the order of  
20 hundreds of days in humans and dogs. The clearance of particulate matter from the  
21 tracheobronchial region is generally recognized as being biphasic or multiphasic (Raabe, 1982).  
22 Some studies have shown that particles are cleared from large, intermediate, and small airways  
23 with  $t_{1/2}$  of 0.5, 2.5, and 5 h, respectively. However, reports have indicated that clearance from  
24 airways is biphasic and that the long-term component for humans may take much longer for a  
25 significant fraction of particles deposited in this region, and may not be complete within 24 h as  
26 generally believed (Stahlhofen et al., 1990; ICRP, 1994).

27 Although most of the particulate matter will be cleared from the tracheobronchial region  
28 towards the larynx and ultimately swallowed, the contribution of this fraction relative to  
29 carcinogenic potential is unclear. With the exception of conditions of impaired bronchial  
30 clearance, the desorption  $t_{1/2}$  for particle-associated organics is generally longer than the  
31 tracheobronchial clearance times, thereby making uncertain the importance of this fraction relative  
32 to toxicity in the respiratory tract (Pepelko, 1987). However, Gerde et al. (1991a) showed that  
33 for low-dose exposures, particle-associated PAHs were released rapidly at the site of deposition.  
34 The relationship between the early clearance of poorly soluble particles of  $4 \mu\text{m}$  aerodynamic  
35 diameter from the tracheobronchial regions and their longer-term clearance from the alveolar  
36 region is illustrated in Figure 3-2.

1 Cuddihy and Yeh (1986) reviewed respiratory tract clearance of particles inhaled by  
2 humans. Depending on the type of particle (ferric oxide, Teflon discs, or albumin microspheres),  
3 the technique employed, and the anatomic region (midtrachea, trachea, or main bronchi), particle  
4 velocity (moved by mucociliary transport) ranged from 2.4 to 21.5 mm/min. The highest  
5 velocities were recorded for midtracheal transport, and the lowest were for main bronchi. In one  
6 study, an age difference was noted for tracheal mucociliary transport velocity (5.8 mm/min for  
7 individuals less than 30 years of age and 10.1 mm/min for individuals over 55 years of age).

8 Cuddihy and Yeh (1986) described salient points to be considered when estimating  
9 particle clearance velocities from tracheobronchial regions: these include respiratory tract airway  
10 dimensions, calculated inhaled particle deposition fractions for individual airways, and thoracic (A  
11 + TB) clearance measurements. Predicted clearance velocities for the trachea and main bronchi  
12 were found to be similar to those experimentally determined for inhaled radiolabeled particles, but  
13 not those for intratracheally instilled particles. The velocities observed for inhalation studies were  
14 generally lower than those of instillation studies. Figure 3-3 illustrates a comparison of the short-  
15 term clearance of inhaled particles by human subjects and the model predictions for this clearance.  
16 However, tracheobronchial clearance via the mucociliary escalator is of limited importance for  
17 long-term clearance.

18 Exposure of F344 rats to whole DPM at concentrations of 0.35, 3.5, or 7.1 mg/m<sup>3</sup> for up  
19 to 24 mo did not significantly alter tracheal mucociliary clearance as assessed by clearance of  
20 <sup>99m</sup>Tc-macroaggregated albumin instilled into the trachea (Wolff et al., 1987). The authors stated  
21 that measuring retention would yield estimates of clearance efficiency comparable to measuring  
22 the velocity for transport of the markers in the trachea. The results of this study were in  
23 agreement with similar findings of unaltered tracheal mucociliary clearance in rats exposed to  
24 DPM (0.21, 1.0, or 4.4 mg/m<sup>3</sup>) for up to 4 mo (Wolff and Gray, 1980). However, the 1980 study  
25 by Wolff and Gray, as well as an earlier study by Battigelli et al. (1966), showed that acute  
26 exposure to high concentrations of diesel exhaust soot (1.0 and 4.4 mg/m<sup>3</sup> in the study by Wolff  
27 and Gray [1980] and 8 to 17 mg/m<sup>3</sup> in the study by Battigelli et al. [1966]) produced transient  
28 reductions in tracheal mucociliary clearance. Battigelli et al. (1966) also noted that the  
29 compromised tracheal clearance was not observed following cessation of exhaust exposure.

30 That tracheal clearance does not appear to be significantly impaired or is impaired only  
31 transiently following exposure to high concentrations of DPM is consistent with the absence of  
32 pathological effects in the tracheobronchial region of the respiratory tract in experimental animals  
33 exposed to DPM. The apparent retention of a fraction of the deposited dose in  
34 the airways could be cause for some concern regarding possible effects in this region, especially in  
35 light of the results from simulation studies by Gerde et al. (1991b) suggesting that release of  
36 PAHs from particles may occur within minutes and therefore at the site of initial deposition.

1 However, the absence of effects in the TB areas in long-term DPM studies and experimental  
2 evidence that particle-associated PAHs are released at the site of particle deposition together  
3 suggest that these PAHs and other organics may be of lesser importance in tumorigenic responses  
4 of rats than originally suspected. On the other hand, however, a larger fraction of particles are  
5 translocated to the interstitium of the respiratory tract in primates (and therefore presumably in  
6 humans) than in rats, including the interstitium of the respiratory bronchioles, an anatomical site  
7 absent in rats (Section 3.6) (Nikula et al., 1997a,b). Moreover, eluted PAHs in the TB region are  
8 retained longer than those in the alveoli (Gerde et al., 1999), allowing time for activation. Thus  
9 PAHs may have a role in human response to diesel exhaust that cannot be evaluated with the rat  
10 model.

11 Also, impairment of mucociliary clearance function as a result of exposure to occupational  
12 or environmental respiratory tract toxicants or to cigarette smoke may significantly enhance the  
13 retention of particles in the TB region. For example, Vastag et al. (1986) demonstrated that not  
14 only smokers with clinical symptoms of bronchitis but also symptom-free smokers have  
15 significantly reduced mucociliary clearance rates. Although impaired tracheobronchial clearance  
16 could conceivably have an impact on the effects of deposited DPM in the conducting airways, it  
17 does not appear to be relevant to the epigenetic mechanism likely responsible for diesel exhaust-  
18 induced rat pulmonary tumors.

19 Poorly soluble particles such as DPM that are deposited within the TB region are cleared  
20 predominantly by mucociliary transport towards the oropharynx, followed by swallowing. Poorly  
21 soluble particles may also be cleared by traversing the epithelium by endocytotic processes, and  
22 enter the peribronchial region. Clearance may occur following phagocytosis by airway  
23 macrophages, located on or beneath the mucous lining throughout the bronchial tree, or via  
24 macrophages that enter the airway lumen from the bronchial or bronchiolar mucosa (Robertson,  
25 1980).

### 26 27 **3.3.2.3. A Region**

28 A number of investigators have reported on the alveolar clearance kinetics of human  
29 subjects. Bohning et al. (1980) examined alveolar clearance in eight humans who had inhaled  
30 <0.4 mg of <sup>85</sup>Sr-labeled polystyrene particles (3.6 ± 1.6 μm diam.). A double-exponential model  
31 best described the clearance of the particles and provided t<sub>1/2</sub> values of 29 ± 19 days and 298 ±  
32 114 days for short-term and long-term phases, respectively. It was noted that of the particles  
33 deposited in the alveolar region, 75% ± 13% were cleared via the long-term phase. Alveolar  
34 retention t<sub>1/2</sub> values of 330 and 420 days were reported for humans who had inhaled  
35 aluminosilicate particles of MMAD 1.9 and 6.1 μm (Bailey et al., 1982). In a comprehensive  
36 study Bailey et al. (1985) followed the long-term retention of inhaled particles in a human

1 respiratory tract. The retention of 1 and 4  $\mu\text{m}$  fused aluminosilicate particles labeled with  
2 strontium-85 and yttrium-88, respectively, was followed in male volunteers for about 533 days.  
3 Approximately 7% of the initial lung deposit of 1  $\mu\text{m}$  particles and 40% of the 4  $\mu\text{m}$  particles  
4 were associated with a rapid clearance phase corresponding to the calculated tracheobronchial  
5 deposits. Retention of the remaining material followed a two-component exponential function,  
6 with phases having half-times of the order of tens of days and several hundred days, respectively.

7 Quantitative data on clearance rates in humans having large lung burdens of particulate  
8 matter are lacking. Bohning et al. (1982) and Cohen et al. (1979), however, did provide evidence  
9 for slower clearance in smokers, and Freedman and Robinson (1988) reported slower clearance  
10 rates in coal miners who had mild pneumoconiosis with presumably high lung burdens of coal  
11 dust. Although information on particle burden and particle overload relationships in humans is  
12 much more limited than in experimental animal models, inhibition of clearance does seem to  
13 occur. Stöber et al. (1967) estimated a clearance  $t_{1/2}$  of 4.9 years in coal miners with nil or slight  
14 silicosis, based on postmortem lung burdens. The lung burdens and estimated exposure histories  
15 ranged from 2 to 50 mg/g of lung or more, well above the value at which clearance impairment is  
16 observed in the rat. Furthermore, impaired clearance resulting from smoking or exposure to other  
17 respiratory toxicants may increase the possibility of an enhanced particle accumulation effect  
18 resulting from exposure to other particle sources such as DPM.

19 Normal alveolar clearance rates in laboratory animals exposed to DPM have been reported  
20 by a number of investigators (Table 3-2). Because the rat is, historically, the species for which  
21 experimentally induced lung cancer data are available and for which most clearance data exist, it is  
22 the species most often used for assessing human risk, and reviews of alveolar clearance studies  
23 have been generally limited to this species.

24 Chan et al. (1981) subjected 24 male F344 rats to nose-only inhalation of DPM (6 mg/m<sup>3</sup>)  
25 labeled with <sup>131</sup>Ba or <sup>14</sup>C for 40 to 45 min and assessed total lung deposition, retention, and  
26 elimination. Based on radiolabel inventory, the deposition efficiency in the respiratory tract was  
27 15% to 17%. Measurement of <sup>131</sup>Ba label in the feces during the first 4 days following exposure  
28 indicated that 40% of the deposited DPM was eliminated via mucociliary clearance. Clearance of  
29 the particles from the lower respiratory tract followed a two-phase elimination process consisting  
30 of a rapid ( $t_{1/2}$  of 1 day) elimination by mucociliary transport and a slower ( $t_{1/2}$  of 62 days)  
31 macrophage-mediated alveolar clearance. This study provided data for normal alveolar clearance  
32 rates of DPM not affected by prolonged exposure or particle overloading.

33 Several studies have investigated the effects of exposure concentration on the alveolar  
34 clearance of DPM by laboratory animals. Wolff et al. (1986, 1987) provided clearance data ( $t_{1/2}$ )  
35 and lung burden values for F344 rats exposed to diesel exhaust for 7 h/day, 5 days/week for 24  
36 mo. Exposure concentrations of 0.35, 3.5, and 7.1 mg of DPM/m<sup>3</sup> were employed in this whole

1 body-inhalation exposure experiment. Intermediate (hours-days) clearance of  $^{67}\text{Ga}_2\text{O}_3$  particles  
2 (30 min, nose-only inhalation) was assessed after 6, 12, 18, and 24 mo of exposure at all of the  
3 DPM concentrations. A two-component function described the clearance of the administered  
4 radiolabel:

$$5 \quad F_{(t)} = A \exp(-0.693 t/t_1) + B \exp(-0.693 t/t_2), \quad (3-1)$$

7  
8 where  $F_{(t)}$  was the percentage retained throughout the respiratory tract,  $A$  and  $B$  were the  
9 magnitudes of the two components (component  $A$  included nasal, lung, and gastrointestinal  
10 clearance, while component  $B$  represented intermediate lung clearance) and  $\tau_1$  and  $\tau_2$  were the  
11 half-times for the  $A$  and  $B$  components, respectively. The early clearance half-times ( $\tau_1$ ), were  
12 similar for rats in all exposure groups at all time points except in the high-exposure ( $7.1 \text{ mg/m}^3$ )  
13 group following 24 mo of exposure, which was faster than the controls. Significantly longer  $B$   
14 component retention half-times, representing intermediate clearance probably from nonciliated  
15 structures such as alveolar ducts and alveoli, were noted after as little as 6 mo exposure to DPM  
16 at  $7.1 \text{ mg/m}^3$  and 18 mo exposure to  $3.5 \text{ mg/m}^3$ .

17       Nose-only exposures to  $^{134}\text{Cs}$  fused aluminosilicate particles (FAP) were used to assess  
18 long-term (weeks-months) clearance. Following 24-mo exposure to DPM, long-term clearance of  
19  $^{134}\text{Cs}$ -FAP was significantly ( $p < 0.01$ ) altered in the  $3.5$  (cumulative exposure [ $C \times T$ ] of  $11,760$   
20  $\text{mg}\cdot\text{h/m}^3$ ) and  $7.1 \text{ mg/m}^3$   $C \times T = 23,520 \text{ mg}\cdot\text{h/m}^3$ ) exposure groups ( $t_{1/2}$  of 264 and 240 days,  
21 respectively) relative to the  $0.35 \text{ mg/m}^3$  and control groups ( $t_{1/2}$  of 81 and 79 days, respectively).  
22 Long-term clearance represents the slow component of particle removal from the alveoli. The  
23 decreased clearance correlated with the greater particle burden in the lungs of the  $3.5$  and  $7.1$   
24  $\text{mg/m}^3$  exposure groups. Based on these findings, the cumulative exposure of  
25  $> 11,760 \text{ mg}\cdot\text{h/m}^3$  (or  $3.5 \text{ mg/m}^3$  for a lifetime exposure) represented a particle overload condition  
26 resulting in compromised alveolar clearance mechanisms; the clearance rate at the lowest  
27 concentration ( $0.35 \text{ mg/m}^3$ ; cumulative exposure of  $118 \text{ mg}\cdot\text{h/m}^3$ ) was not different from control  
28 rates (Figure 3-4).

29       Heinrich et al. (1986) exposed rats 19 h/day, 5 days/week for 2.5 years to DPM at a  
30 particle concentration of about  $4 \text{ mg/m}^3$ , equal to a  $C \times T$  of  $53,200 \text{ mg}\cdot\text{h/m}^3$ . The deposition in  
31 the alveolar region was estimated to equal 60 mg. The lung particle burden was apparently  
32 sufficient to result in a “particle overload” condition (Section 3.4). With respect to the organic  
33 matter adsorbed onto the particles, the authors estimated that over the 2.5-year period, 6-15 mg  
34 of particle-bound organic matter had been deposited and was potentially available for biological

1 effects. This estimation was based on the analysis of the diesel exhaust used in the experiments,  
2 values for rat ventilatory functions, and estimates of deposition and clearance.

3 Accumulated burden of DPM in the lungs following an 18-mo, 7 h/day, 5 days/week  
4 exposure to diesel exhaust was reported by Griffis et al. (1983). Male and female F344 rats  
5 exposed to 0.15, 0.94, or 4.1 mg DPM/m<sup>3</sup> were sacrificed at 1 day and 1, 5, 15, 33, and 52 weeks  
6 after exposure, and DPM was extracted from lung tissue dissolved in tetramethylammonium  
7 hydroxide. Following centrifugation and washing of the supernatant, DPM content of the tissue  
8 was quantitated using spectrophotometric techniques. The analytical procedure was verified by  
9 comparing results to recovery studies using known amounts of DPM with lungs of unexposed  
10 rats. Lung burdens were 0.035, 0.220, and 1.890 mg/g lung tissue, respectively, in rats exposed  
11 to 0.15, 0.94, and 4.1 mg DPM/m<sup>3</sup>. Long-term retention for the 0.15 and 0.94 mg/m<sup>3</sup> groups had  
12 estimated half-times of 87 ± 28 and 99 ± 8 days, respectively. The retention  $t_{1/2}$  for the 4.1-mg/m<sup>3</sup>  
13 exposure group was 165 ± 8 days, which was significantly ( $p < 0.0001$ ) greater than those of the  
14 lower exposure groups. The 18-mo exposures to 0.15 or 0.96 mg/m<sup>3</sup> levels of DPM  $C \times T$   
15 equivalent of 378 and 2,368 mg·h/m<sup>3</sup>, respectively) did not affect clearance rates, whereas the  
16 exposure to the 4.1 mg/m<sup>3</sup> concentration  $C \times T = 10,332$  mg·h/m<sup>3</sup>) resulted in impaired clearance.

17 Lee et al. (1983) described the clearance of DPM (7 mg/m<sup>3</sup> for 45 min or 2 mg/m<sup>3</sup> for 140  
18 min) by F344 rats (24 per group) and Hartley guinea pigs exposed by nose-only inhalation with no  
19 apparent particle overload in the lungs as being in three distinct phases. The exposure protocols  
20 provided comparable total doses based on a <sup>14</sup>C radiolabel. <sup>14</sup>CO<sub>2</sub> resulting from combustion of  
21 <sup>14</sup>C-labeled diesel fuel was removed by a diffusion scrubber to avoid erroneous assessment of <sup>14</sup>C  
22 intake by the animals. Retention of the radiolabeled particles was determined up to 335 days after  
23 exposure and resulted in a three-phase clearance with retention  $t_{1/2}$  values of 1, 6, and 80 days.  
24 The three clearance phases are taken to represent removal of tracheobronchial deposits by the  
25 mucociliary escalator, removal of particles deposited in the respiratory bronchioles, and alveolar  
26 clearance, respectively. Species variability in clearance of DPM was also demonstrated because  
27 the Hartley guinea pigs exhibited negligible alveolar clearance from day 10 to day 432 following a  
28 45-min exposure to a DPM concentration of 7 mg/m<sup>3</sup>. Initial deposition efficiency (20% ± 2%)  
29 and short-term clearance were, however, similar to those for rats.

30 Lung clearance in male F344 rats preexposed to DPM at 0.25 or 6 mg/m<sup>3</sup> 20 h/day,  
31 7 days/week for periods lasting from 7 to 112 days was studied by Chan et al. (1984). Following  
32 this preexposure protocol, rats were subjected to 45-min nose-only exposure to <sup>14</sup>C-DE, and  
33 alveolar clearance of radiolabel was monitored for up to 1 year. Two models were proposed: a  
34 normal biphasic clearance model and a modified lung retention model that included a slow-  
35 clearing residual component to account for sequestered aggregates of macrophages. The first  
36 model described a first-order clearance for two compartments:  $R(t) = Ae^{-u_1t} + Be^{-u_2t}$ . This yielded

1 clearance  $t_{1/2}$  values of 166 and 562 days for rats preexposed to  $6.0 \text{ mg/m}^3$  for 7 and 62 days,  
2 respectively. These values were significantly ( $p < 0.05$ ) greater than the retention  $t_{1/2}$  of  $77 \pm 17$   
3 days for control rats. The same retention values for rats of the  $0.25 \text{ mg/m}^3$  groups were  $90 \pm 14$   
4 and  $92 \pm 15$  days, respectively, for 52- and 112-day exposures and were not significantly different  
5 from controls. The two-compartment model represents overall clearance of the tracer particles,  
6 even if some of the particles were sequestered in particle-laden macrophages with substantially  
7 slower clearance rates. For the second model, which excluded transport of the residual fractions  
8 in sequestered macrophage aggregates, slower clearance was observed in the group with a lung  
9 burden of  $6.5 \text{ mg}$  (exposed to  $6.0 \text{ mg/m}^3$  for 62 days), and no clearance was observed in the  $11.8$   
10  $\text{mg}$  group (exposed to  $6.0 \text{ mg/m}^3$  for 112 days). Clearance was shown to be dependent on the  
11 initial burden of particles, and therefore the clearance  $t_{1/2}$  would increase in higher exposure  
12 scenarios. This study emphasizes the importance of particle overloading of the lung and the  
13 ramifications on clearance of particles; the significant increases in half-times indicate an increasing  
14 impairment of the alveolar macrophage mobility and subsequent transition into an overload  
15 condition as is discussed further in Section 3.4.

16 Long-term alveolar clearance rates of particles in various laboratory animals and humans  
17 have been reviewed by Pepelko (1987). Although retention  $t_{1/2}$  varies both among and within  
18 species and is also dependent on the physicochemical properties of the inhaled particles, the  
19 retention  $t_{1/2}$  for humans is much longer ( $>8 \text{ mo}$ ) than the average retention  $t_{1/2}$  of 60 days for rats.

20 Clearance from the A region occurs via a number of mechanisms and pathways, but the  
21 relative importance of each is not always certain and may vary between species. Particle removal  
22 by macrophages comprises the main nonabsorptive clearance process in this region. Alveolar  
23 macrophages reside on the epithelium, where they phagocytize and transport deposited material,  
24 which they contact by random motion or via directed migration under the influence of local  
25 chemotactic factors (Warheit et al., 1988).

26 Particle-laden macrophages may be cleared from the A region along a number of pathways  
27 (U.S. EPA, 1996). Uningested particles or macrophages in the interstitium may traverse the  
28 alveolar-capillary endothelium, directly entering the blood (Raabe, 1982; Holt, 1981); endocytosis  
29 by endothelial cells followed by exocytosis into the vessel lumen seems, however, to be restricted  
30 to particles  $< 0.1 \mu\text{m}$  diameter, and may increase with increasing lung burden (Lee et al., 1985;  
31 Oberdörster, 1988). Once in the systemic circulation, transmigrated macrophages, as well as  
32 uningested particles, can travel to extrapulmonary organs.

33 Alveolar macrophages constitute an important first-line cellular defense mechanism against  
34 inhaled particles that deposit in the alveolar region of the lung. It is well established that a host of  
35 diverse materials, including DPM, are phagocytized by AMs shortly after deposition (White and  
36 Garg, 1981; Lehnert and Morrow, 1985) and that such cell-contained particles are generally

1 rapidly sequestered from both the extracellular fluid lining in the alveolar region and the  
2 potentially sensitive alveolar epithelial cells. In addition to this role in compartmentalizing  
3 particles from other lung constituents, AMs are prominently involved in mediating the clearance  
4 of relatively insoluble particles from the air spaces (Lehnert and Morrow, 1985). Although the  
5 details of the actual process have not been delineated, AMs with their particle burdens gain  
6 access and become coupled to the mucociliary escalator and are subsequently transported from  
7 the lung via the conducting airways. Although circumstantial, numerous lines of evidence indicate  
8 that such AM-mediated particle clearance is the predominant mechanism by which relatively  
9 insoluble particles are removed from the alveolar region of the lungs (Gibb and Morrow, 1962;  
10 Ferin, 1982; Harmsen et al., 1985; Lehnert and Morrow, 1985; Powdrill et al., 1989).

11 The removal characteristics for particles deposited in the alveolar region of the lung have  
12 been descriptively represented by numerous investigators as a multicompartment or  
13 multicomponent process in which each component follows simple first-order kinetics (Snipes and  
14 Clem, 1981; Snipes et al., 1988; Lee et al., 1983). Although the various compartments can be  
15 described mathematically, the actual physiological mechanisms determining these differing  
16 clearance rates have not been well characterized.

17 Lehnert et al. (1988, 1989) performed studies using laboratory rats to examine  
18 particle-AM relationships over the course of alveolar clearance of low to high lung burdens of  
19 noncytotoxic microspheres (2.13  $\mu\text{m}$  diam.) to obtain information on potential AM-related  
20 mechanisms that form the underlying bases for kinetic patterns of alveolar clearance as a function  
21 of particle lung burdens. The intratracheally instilled lung burdens varied from  $1.6 \times 10^7$  particles  
22 (about 85  $\mu\text{g}$ ) for the low lung burden to  $2.0 \times 10^8$  particles (about 1.06 mg) for the mid-dose and  
23  $6.8 \times 10^8$  particles (about 3.6 mg) for the highest lung burden. The lungs were lavaged at various  
24 times postexposure and the numbers of spheres in each macrophage counted. Although such  
25 experiments provide information regarding the response of the lung to particulate matter,  
26 intratracheal instillation is not likely to result in the same depositional characteristics as inhalation  
27 of particles. Therefore, it is unlikely that the response of alveolar macrophages to these different  
28 depositional characteristics will be quantitatively similar.

29 The  $t_{1/2}$  values of both the early and later components of clearance were virtually identical  
30 following deposition of the low and medium lung burdens. For the highest lung burden,  
31 significant prolongations were found in both the early, more rapid, as well as the slower  
32 component of alveolar clearance. The percentages of the particle burden associated with the  
33 earlier and later components, however, were similar to those of the lesser lung burdens. On the  
34 basis of the data, the authors concluded that translocation of AMs from alveolar spaces by way of  
35 the conducting airways is fundamentally influenced by the particle burden of the cells so  
36 translocated. In the case of particle overload that occurred at the highest lung burden, the

1 translocation of AMs with the heaviest cellular burdens of particles (i.e., greater than about  
2 100 microspheres per AM) was definitely compromised.

3 On the other hand, analysis of the disappearance of AMs with various numbers of particles  
4 indicates that the particles may not exclusively reflect the translocation of AMs from the lung.  
5 The observations are also consistent with a gradual redistribution of retained particles among the  
6 AMs in the lung concurrent with the removal of particle-containing AMs via the conducting  
7 airways. Experimental support suggestive of potential processes for such particle redistribution  
8 comes from a variety of investigations involving AMs and other endocytic cells (Heppleston and  
9 Young, 1973; Evans et al., 1986; Aronson, 1963; Sandusky et al., 1977; Heppleston, 1961; Riley  
10 and Dean, 1978).

### 11 12 **3.3.3. Translocations of Particles to Extra-Alveolar Macrophage Compartment Sites**

13 Although the phagocytosis of particles by cells free within the lung and the mucociliary  
14 clearance of the cells with their particulate matter burdens represent the most prominent  
15 mechanisms that govern the fate of particles deposited in the alveolar region, other mechanisms  
16 exist that can affect both the retention characteristics of relatively insoluble particles in the lung  
17 and the lung clearance pathways for the particles. One mechanism is endocytosis of particles by  
18 alveolar lining (Type I) cells (Sorokin and Brain, 1975; Adamson and Bowden, 1978, 1981) that  
19 normally provide >90% of the cell surface of the alveoli in the lungs of a variety of mammalian  
20 species (Crapo et al., 1983). This process may be related to the size of the particles that deposit  
21 in the lungs and the numbers of particles that are deposited. Adamson and Bowden (1981) found  
22 that with increasing loads of carbon particles (0.03  $\mu\text{m}$  diam.) instilled in the lungs of mice, more  
23 free particles were observed in the alveoli within a few days. The relative abundance of particles  
24 endocytosed by Type I cells also increased with increasing lung burdens of the particles, but  
25 instillation of large particles (1.0  $\mu\text{m}$ ) rarely resulted in their undergoing endocytosis. A 4 mg  
26 burden of 0.1  $\mu\text{m}$  diameter latex particles is equivalent to  $8 \times 10^{12}$  particles, whereas a 4 mg  
27 burden of 1.0  $\mu\text{m}$  particles is composed of  $8 \times 10^9$  particles. Regardless, DPM with volume  
28 median diameters between 0.05 and 0.3  $\mu\text{m}$  (Frey and Corn, 1967; Kittleson et al., 1978) would  
29 be expected to be within the size range for engulfment by Type I cells should suitable encounters  
30 occur. Indeed, it has been demonstrated that DPM is endocytosed by Type I cells in vivo (White  
31 and Garg, 1981).

32 Unfortunately, information on the kinetics of particle engulfment (endocytosis) by Type I  
33 cells relative to that by AMs is scanty. Even when relatively low burdens of particulate matter are  
34 deposited in the lungs, some fraction of the particles usually appears in the regional lymph nodes  
35 (Ferlin and Fieldstein, 1978; Lehnert, 1989). As will be discussed, endocytosis of particles by  
36 Type I cells is an initial, early step in the passage of particles to the lymph nodes. Assuming

1 particle phagocytosis is not sufficiently rapid or perfectly efficient, increasing numbers of particles  
2 would be expected to gain entry into the Type I epithelial cell compartment during chronic aerosol  
3 exposures. Additionally, if particles are released on a continual basis by AMs that initially  
4 sequestered them after lung deposition, some fraction of the “free” particles so released could also  
5 undergo passage from the alveolar space into Type I cells.

6 The endocytosis of particles by Type I cells represents only the initial stage of a process  
7 that can lead to the accumulation of particles in the lung’s interstitial compartment and the  
8 subsequent translocation of particles to the regional lymph nodes. As shown by Adamson and  
9 Bowden (1981), a vesicular transport mechanism in the Type I cell can transfer particles from the  
10 air surface of the alveolar epithelium into the lung’s interstitium, where particles may be  
11 phagocytized by interstitial macrophages or remain in a “free” state for a poorly defined period  
12 that may be dependent on the physicochemical characteristics of the particle. The lung’s  
13 interstitial compartment accordingly represents an anatomical site for the retention of particles in  
14 the lung, especially so for primates. Whether or not AMs, and perhaps polymorphonuclear  
15 neutrophils (PMNs) that have gained access to the alveolar space compartment and phagocytize  
16 particles there, also contribute to the particle translocation process into the lung’s interstitium  
17 remains a controversial issue.

18 Translocation of particulate matter to the various interstitial spaces within the lung is a  
19 prominent phenomenon occurring at least at high (occupational) exposures that has been  
20 examined extensively for both DPM and coal dust in a species comparison between rats and  
21 primates (Nikula et al., 1997a,b). Detailed pulmonary morphometry conducted on F344 rats and  
22 cynomolgus monkeys that had been exposed for 24 months to occupational levels of DPM (1.95  
23 mg/m<sup>3</sup>; see Lewis et al., 1989) showed major differences in the pulmonary sites of particulate  
24 deposition. In rats about 73% of DPM was present in the alveolar ducts/alveoli and 27% in  
25 interstitial compartments; for monkeys the corresponding figures were markedly different at 43%  
26 and 57%. The corresponding pulmonary histopathology confirmed that both species were  
27 affected, although rats are more sensitive, as incidence and severity scores for alveolar effects  
28 ranged from 15 of 15 with severity scores from 1-4 (minimal to moderate), whereas for monkeys  
29 the corresponding values were only 4 of 15 at a range of 0-2 (not observed to minimal).  
30 Similarly, both species exhibited histopathology at the interstitial sites of deposition but with  
31 effects in monkeys being slightly more severe (1 of 15 graded as slight, 14 of 15 graded as  
32 minimal) than those in rats (14 of 15 graded as slight, 1 of 15 graded as minimal). The basis for  
33 this interspecies difference may be due to any number of clear contrasts that exist between rat and  
34 primate lungs, including anatomical (primates and humans have respiratory bronchioles whereas  
35 rats do not), kinetic (primates and human clearance processes allow more residence time of  
36 particles in the lung than do those in rats), or morphological (primates and humans have more

1 interstitial tissue, more and thicker pleura, and wider interstitial spaces than do rats). The analysis  
2 of Kuempel (2000) using human occupational data clearly showed that models require an  
3 interstitialization process to provide adequate fits to the empirical human (miners') lung  
4 deposition data discussed in that study. Hypotheses about possible mechanisms for the  
5 interstitialization process are scant, although Harmsen et al. (1985) provided some evidence in  
6 dogs that migration of AMs may contribute to the passage of particles to the interstitial  
7 compartment and also may be involved in the subsequent translocation of particles to draining  
8 lymph nodes. Translocation to the extrapulmonary regional lymph nodes apparently can involve  
9 the passage of free particles as well as particle-containing cells via lymphatic channels in the lungs  
10 (Harmsen et al., 1985; Ferin and Fieldstein, 1978; Lee et al., 1985). Further, it has been noted  
11 that particles accumulate both more rapidly and more abundantly in lymph nodes that receive  
12 lymphatic drainage from the lung (Ferin and Feldstein, 1978; Lee et al., 1985). As a final point, it  
13 should be stressed that further investigation is required to confirm the character and even  
14 existence of the interstitialization process in the lungs of humans with exposures to particles at  
15 lower environmental concentrations, or to submicrometer particles such as DPM.

#### 16 17 **3.3.3.1. Clearance Kinetics**

18 The clearance kinetics of PM have been reviewed in the PM CD (U.S. EPA, 1996) and by  
19 Schlesinger et al. (1997), the results of which indicate that clearance kinetics may be profoundly  
20 influenced by several factors. The influence of time, for example, is definitively showed by the  
21 work of Bailey et al. (1985; discussed above), who showed that the rate of clearance from the  
22 pulmonary region to the GI tract decreased nearly fourfold from initial values to those noted at  
23 200 days and beyond after particle inhalation.

#### 24 25 **3.3.3.2. Interspecies Patterns of Clearance**

26 The inability to study the retention of certain materials in humans for direct risk  
27 assessment requires the use of laboratory animals. Adequate toxicological assessment  
28 necessitates that interspecies comparisons consider aspects of dosimetry including knowledge of  
29 clearance rates and routes. The basic mechanisms and overall patterns of clearance from the  
30 respiratory tract are similar in humans and most other mammals. Regional clearance rates,  
31 however, can show substantial variation between species, even for similar particles deposited  
32 under comparable exposure conditions (U.S. EPA, 1996; Schlesinger et al., 1997; Snipes et al.,  
33 1989).

34 In general, there are species-dependent rate constants for various clearance pathways.  
35 Differences in regional and total clearance rates between some species are a reflection of  
36 differences in mechanical clearance processes. For consideration in assessing particle dosimetry,

1 the end result of interspecies differences in clearance is that the retained doses in the lower  
2 respiratory tract can differ between species, which may result in differences in response to similar  
3 particulate exposures.  
4

### 5 **3.3.3.3. Clearance Modifying Factors and Susceptible Populations**

6 A number of host and environmental factors may modify clearance kinetics and may  
7 consequently make individuals exhibiting or afflicted with these factors particularly susceptible to  
8 the effects resulting from exposure to DPM. These include age, gender, physical activity,  
9 respiratory tract disease, and inhalation of irritants (U.S. EPA, 1996, Section 10.4.2.5).  
10 Respiratory tract clearance appears to be prolonged in a number of pathophysiological conditions in  
11 humans, including chronic sinusitis, chronic bronchitis, asthma, chronic obstructive lung disease,  
12 and various acute respiratory infections.  
13

### 14 **3.3.3.4. Respiratory Tract Disease**

15 Earlier studies reviewed in the PM CD (U.S. EPA, 1996) noted that various respiratory  
16 tract diseases are associated with alterations in overall clearance and clearance rates. Prolonged  
17 nasal mucociliary clearance in humans is associated with chronic sinusitis or rhinitis, and cystic  
18 fibrosis. Bronchial mucus transport may be impaired in people with bronchial carcinoma, chronic  
19 bronchitis, asthma, and various acute infections. In certain of these cases, coughing may enhance  
20 mucus clearance, but it generally is effective only if excess secretions are present.

21 The rates of A region particle clearance are reduced in humans with chronic obstructive  
22 lung disease and in laboratory animals with viral infections, whereas the viability and functional  
23 activity of macrophages are impaired in human asthmatics and in animals with viral-induced lung  
24 infections (U.S. EPA, 1996). However, any modification of functional properties of macrophages  
25 appears to be injury specific, reflecting the nature and anatomic pattern of disease.  
26

## 27 **3.4. PARTICLE OVERLOAD**

### 28 **3.4.1. Introduction**

29 Some experimental studies using laboratory rodents employed high exposure  
30 concentrations of relatively nontoxic, poorly soluble particles. These particle loads interfered with  
31 normal clearance mechanisms, producing clearance rates different from those that would  
32 occur at lower exposure levels. Prolonged exposure to high particle concentrations is associated  
33 with what is termed particle overload. This is defined as the overwhelming of macrophage-  
34 mediated clearance by the deposition of particles at a rate exceeding the capacity of that clearance  
35 pathway. Aspects and occurrence of this phenomenon have already been alluded to in earlier  
36 portions of this chapter on alveolar clearance (Section 3.3.2.3). The relevance of this

1 phenomenon for human risk assessment has long been the object of scientific inquiry. A  
2 monograph on this matter and many others relevant to DPM has appeared (ILSI, 2000), and the  
3 results, opinions, and judgments put forth therein are used extensively in this chapter and in this  
4 assessment.

5 Wolff et al. (1987) used  $^{134}\text{Cs}$ -labeled fused aluminosilicate particles to measure alveolar  
6 clearance in rats following 24-mo exposure to low, medium, and high concentrations of diesel  
7 exhaust (targeted concentrations of DPM of 0.35, 3.5 and  $7.1 \text{ mg/m}^3$ ). The short-term  
8 component of the multicomponent clearance curves was similar for all groups, but long-term  
9 clearance was retarded in the medium and high exposure groups (Figure 3-4). The half times of  
10 the long-term clearance curves were 79, 81, 264, and 240 days, respectively, for the control, low-,  
11 medium-, and high-exposure groups. Clearance was overloaded at the high and medium but not  
12 at the low exposure level. Lung burdens of DPM were measured after 6, 12, 18, and 24 mo of  
13 exposure. The results (Figure 3-5) indicate that the lung burden of freshly deposited particles was  
14 appreciably increased in the two highest exposures post 6 mo., whereas the lung burden at the  
15 low-exposure level remained the same throughout all time periods examined.

16 Morrow (1988) has proposed that the condition of particle overloading in the lungs is  
17 caused by a loss in the mobility of particle-engorged AMs and that such an impediment is related  
18 to the cumulative volumetric load of particles in the AMs. Morrow (1988) has further estimated  
19 that the clearance function of an AM may be completely impaired when the particle burden in the  
20 AM is of a volumetric size equivalent to about 60% of the normal volume of the AM. Morrow's  
21 hypothesis was the initial basis for the physiology-oriented multicompartmental kinetic (POCK)  
22 model derived by Stöber et al. (1989) for estimating alveolar clearance and retention of relatively  
23 insoluble, respirable particles in rats.

24 A revised version of this model refines the characterization of the macrophage pool by  
25 including both the mobile and immobilized macrophages (Stöber et al., 1994). Application of  
26 the revised version of the model to experimental data suggested that lung overload does not cause  
27 a dramatic increase in the total burden of the macrophage pool but results in a great increase in  
28 the particle burden of the interstitial space, a compartment that is not available for macrophage-  
29 mediated clearance. The revised version of the POCK model is discussed in greater detail in the  
30 context of other dosimetry models below.

31 Oberdörster and co-workers (1992) assessed the alveolar clearance of smaller ( $3.3 \mu\text{m}$   
32 diam.) and larger ( $10.3 \mu\text{m}$  diam.) polystyrene particles, the latter of which are volumetrically  
33 equivalent to about 60% of the average normal volume of a rat AM, after intratracheal instillation  
34 into the lungs of rats. Even though both sizes of particles were found to be phagocytized by AMs  
35 within a day after deposition, and the smaller particles were cleared at a normal rate, only minimal

1 lung clearance of the larger particles was observed over an approximately 200-day postinstillation  
2 period, thus supporting the volumetric AM overload hypothesis.

3 It has been hypothesized that when the retained lung burden approaches 1 mg particles/g  
4 lung tissue, overloading will begin in the rat (Morrow, 1988); at 10 mg particles/g lung tissue  
5 macrophage-mediated clearance of particles would effectively cease. Overloading appears to be a  
6 nonspecific effect noted in experimental studies, generally in rats, using many different kinds of  
7 poorly soluble particles (including TiO<sub>2</sub>, volcanic ash, DPM, carbon black, and fly ash) and results  
8 in A region clearance slowing or stasis, with an associated inflammation and aggregation of  
9 macrophages in the lungs and increased translocation of particles into the interstitium (Muhle  
10 et al., 1990; Lehnert, 1990; Morrow, 1994). Following overloading, the subsequent retardation  
11 of lung clearance, accumulation of particles, chronic inflammation, and the interaction of  
12 inflammatory mediators with cell proliferative processes and DNA may lead to the development  
13 of fibrosis, epithelial cell mutations, and fibrosis in rats (Mauderly, 1996). The phenomenon of  
14 overload has been discussed in greater detail in the previous PM CD (U.S. EPA, 1996).

### 15 16 **3.4.2. Relevance to Humans**

17 The relevance of lung overload to humans, and even to species other than laboratory rats  
18 and mice, is not clear. Although likely to be of little relevance for most “real world” ambient  
19 exposures of humans, this phenomenon is of concern in interpreting some long-term experimental  
20 exposure data and perhaps for human occupational exposure. In addition, relevance to humans is  
21 clouded by the suggestion that macrophage-mediated clearance is normally slower and perhaps  
22 less important in humans than in rats (Morrow, 1994), and that there can be significant differences  
23 in macrophage loading between species. Particle overload appears to be an important factor in  
24 the pulmonary carcinogenicity observed in rats exposed to DPM. Studies described in this section  
25 provide additional data showing a particle overload effect. A study by Griffis et al. (1983)  
26 demonstrated that exposure (7 h/day, 5 days/week) of rats to DPM at concentrations of 0.15,  
27 0.94, or 4.1 mg/m<sup>3</sup> for 18 mo resulted in lung burdens of 0.035, 0.220, and 1.89 mg/g of lung  
28 tissue, respectively. The alveolar clearance of those rats with the highest lung burden (1.89 mg/g  
29 of lung) was impaired, as determined by a significantly greater ( $p < 0.0001$ ) retention  $t_{1/2}$  for DPM.  
30 Impaired clearance was reflected in the greater lung burden/exposure concentration ratio at the  
31 highest exposure level. Similarly, in the study by Chan et al. (1984), rats exposed for 20 h/day, 7  
32 days/week to DPM (6 mg/m<sup>3</sup>) for 112 days had an extraordinarily high lung particle burden of  
33 11.8 mg, with no alveolar particle clearance being detected over 1 year.

34 Muhle et al. (1990) indicated that overloading of rat lungs occurred when lung particle  
35 burdens reached 0.5 to 1.5 mg/g of lung tissue and that clearance mechanisms were totally

1 compromised at lung particle burdens  $\geq 10$  mg/g for particles with a specific density close to 1,  
2 observations that are concordant with those of Morrow (1988).

3 Pritchard (1989), utilizing data from a number of diesel exhaust exposure studies,  
4 examined alveolar clearance in rats as a function of cumulative exposure. The resulting analysis  
5 noted a significant increase in retention  $t_{1/2}$  values at exposures above  $10 \text{ mg/m}^3\cdot\text{h/day}$  and also  
6 showed that normal lung clearance mechanisms appeared to be compromised as the lung DPM  
7 burden approached 0.5 mg/g of lung.

8 Animal studies have revealed that impairment of alveolar clearance can occur following  
9 chronic exposure to DPM (Griffis et al., 1983; Wolff et al., 1987; Vostal et al., 1982; Lee et al.,  
10 1983) or a variety of other diverse poorly soluble particles of low toxicity (Lee et al., 1986, 1988;  
11 Ferin and Feldstein, 1978; Muhle et al., 1990). Because high lung burdens of relatively insoluble,  
12 biochemically inert particles result in diminution of normal lung clearance kinetics or in what is  
13 now called particle overloading, this effect appears to be more related to the mass and/or volume  
14 of particles in the lung than to the nature of the particles per se. Particle overload relates only to  
15 poorly soluble particles of low toxicity. It must be noted, however, that some types of particles  
16 may be cytotoxic and impair clearance at lower lung burdens (e.g., crystalline silica may impair  
17 clearance at much lower lung burdens than DPM). Regardless, as pointed out by Morrow (1988),  
18 particle overloading in the lung modifies the dosimetry for particles in the lung and thereby can  
19 alter toxicologic responses.

20 Although quantitative data are limited regarding lung overload associated with impaired  
21 alveolar clearance in humans, impairment of clearance mechanisms appears to occur, and at a  
22 lung burden generally in the range reported to impair clearance in rats, i.e., approximately 1 mg/g  
23 lung tissue. Stöber et al. (1967), in their study of coal miners, reported lung particle burdens of 2  
24 to 50 mg/g lung tissue, for which estimated clearance  $t_{1/2}$  values were very long (4.9 years).  
25 Freedman and Robinson (1988) also reported slower alveolar clearance rates in coal miners, some  
26 of whom had a mild degree of pneumoconiosis. It must be noted, however, that no lung cancer  
27 was reported even among those miners with apparent particle overload.

### 28 29 **3.4.3. Potential Mechanisms for an AM Sequestration Compartment for Particles During** 30 **Particle Overload**

31 Several factors may be involved in the particle-load-dependent retardations in the rate of  
32 particle removal from the lung and the corresponding functional appearance of an abnormally  
33 slow clearing or particle sequestration compartment. As previously mentioned, one potential site  
34 for particle sequestration is the containment of particles in the Type I cells. Information on the  
35 retention kinetics for particles in the Type I cells is not currently available. Also, no

1 morphometric analyses have been performed to date to estimate what fraction of a retained lung  
2 burden may be contained in the Type I cell population of the lung during lung overloading.

3 Another anatomical region in the lung that may be a slow clearing site is the interstitial  
4 compartment (Kuempel, 2000). Little is known about the kinetics of removal of free particles or  
5 particle-containing macrophages from the interstitial spaces, or what fraction of a retained burden  
6 of particles is contained in the lung's interstitium during particle overload. The gradual  
7 accumulation of particles in the regional lymph nodes and the appearance of particles and cells  
8 with associated particles in lymphatic channels and in the peribronchial and perivascular lymphoid  
9 tissue (Lee et al., 1985; White and Garg, 1981) suggest that the mobilization of particles from  
10 interstitial sites via local lymphatics is a continual process.

11 Indeed, it is clear from histologic observations of the lungs of animals chronically exposed  
12 to DPM that Type I cells, the interstitium, the lymphatic channels, and pulmonary lymphoid  
13 tissues could collectively comprise subcompartments of a more generalized slow clearing  
14 compartment.

15 Although these sites must be considered potential contributors to the increased retention  
16 of particles during particle overload, a disturbance in particle-associated AM-mediated clearance  
17 is undoubtedly the predominant cause, inasmuch as, at least in animals, the AMs are the primary  
18 reservoirs of deposited particles. The factors responsible for a failure of AMs to translocate from  
19 the alveolar space compartment in lungs with high particulate matter burdens remain uncertain,  
20 although a hypothesis concerning the process involving volumetric AM burden has been offered  
21 (Morrow, 1988).

22 Other processes also may be involved in preventing particle-laden AMs from leaving the  
23 alveolar compartment under conditions of particle overload in the lung. Clusters or aggregates of  
24 particle-laden AMs in the alveoli are typically found in the lungs of laboratory animals that have  
25 received large lung burdens of a variety of types of particles (Lee et al., 1985), including DPM  
26 (White and Garg, 1981; McClellan et al., 1982). The aggregation of AMs may explain, in part,  
27 the reduced clearance of particle-laden AM during particle overload. The definitive mechanism(s)  
28 responsible for this clustering of AMs has not been elucidated to date. Whatever the underlying  
29 mechanism(s) for the AM aggregation response, it is noteworthy that AMs lavaged from the lungs  
30 of diesel exhaust-exposed animals continue to demonstrate a propensity to aggregate (Strom,  
31 1984). This observation suggests that the surface characteristics of AMs are fundamentally  
32 altered in a manner that promotes their adherence to one another in the alveolar region, and that  
33 AM aggregation may not simply be directly caused by their abundant accumulation as a result of  
34 immobilization by large particle loads. Furthermore, even though overloaded macrophages may  
35 redistribute particle burden to other AMs, clearance may remain inhibited (Lehnert, 1988). This

1 may, in part, be because attractants from the overloaded AMs cause aggregation of those that are  
2 not carrying a particle burden.

### 3 4 **3.5. BIOAVAILABILITY OF ORGANIC CONSTITUENTS PRESENT ON DIESEL** 5 **EXHAUST PARTICLES**

6 Because it has been shown that DPM extract is not only mutagenic but also contains  
7 known carcinogens, the organic fraction was originally considered to be the primary source of  
8 carcinogenicity in animal studies. Since then evidence has been presented that carbon black,  
9 lacking an organic component, is capable of inducing lung cancer at exposure concentrations  
10 sufficient to induce lung particle overload. This suggested that the relatively insoluble carbon  
11 core of the particle may be of greater importance for the pathogenic and carcinogenic processes  
12 observed in the rat inhalation studies conducted at high exposure concentrations. (See Chapter 7  
13 for a discussion of this issue.) However, lung cancer reported in epidemiology studies was  
14 associated with diesel exposure levels far below those inducing particle overload in lifetime  
15 studies in rats. It is therefore reasoned that compounds in the organic fraction of DPM may have  
16 some role in the etiology of human lung cancers.

17 The bioavailability of toxic organic compounds adsorbed to DPM can be influenced by a  
18 variety of factors. Although the agent may be active while present on the particle, most particles  
19 are taken up by AMs, a cell type not generally considered to be a target site. In order to reach the  
20 target site, elution from the particle surface is necessary followed by diffusion and uptake by the  
21 target cell. Metabolism to an active form by either the phagocytes or the target cells is also  
22 required for activity of many of the compounds present.

#### 23 24 **3.5.1. In Vivo Studies**

##### 25 **3.5.1.1. Laboratory Investigations**

26 Several studies reported on the retention of particle-adsorbed organics following  
27 administration to various rodent species. In studies reported by Sun et al. (1982, 1984) and Bond  
28 et al. (1986), labeled organics were deposited on DPM following heating to vaporize away the  
29 organics originally present. Sun et al. (1982) compared the disposition of either pure or diesel  
30 particle-adsorbed benzo[a]pyrene (BaP) following nose-only inhalation by F344 rats. About 50%  
31 of particle-adsorbed BaP was cleared with a half-time of 1 h, predominantly by mucociliary  
32 clearance. The long-term retention of particle-adsorbed <sup>3</sup>H-BaP of 18 days was approximately  
33 230-fold greater than that for pure <sup>3</sup>H-BaP (Sun et al., 1982). At the end of exposure, about 15%  
34 of the <sup>3</sup>H label was found in blood, liver, and kidney. Similar results were reported in a  
35 companion study by Bond et al. (1986), and by Sun et al. (1984) with another PAH, 1-  
36 nitropyrene, except the retention half-time was 36 days.

1 Ball and King (1985) studied the disposition and metabolism of intratracheally instilled  
2 <sup>14</sup>C-labeled 1-NP (>99.9% purity) coated onto DPM. About 50% of the <sup>14</sup>C was excreted within  
3 the first 24 h; 20% to 30% of this appeared in the urine, and 40% to 60% was excreted in the  
4 feces. Traces of radiolabel were detected in the trachea and esophagus. Five percent to 12% of  
5 the radiolabel in the lung co-purified with the protein fraction, indicating some protein binding.  
6 The corresponding DNA fraction contained no <sup>14</sup>C above background levels.

7 Bevan and Ruggio (1991) assessed the bioavailability of BaP adsorbed to DPM from a  
8 5.7-L Oldsmobile diesel engine. In this study, exhaust particles containing 1.03 μg BaP/g  
9 particles were supplemented with exogenous <sup>3</sup>H-BaP to provide 2.62 μg BaP/g of exhaust  
10 particles. In vitro analysis indicated that the supplemented BaP eluted from the particles at the  
11 same rate as the original BaP. Twenty-four hours after intratracheal instillation in Sprague-  
12 Dawley rats, 68.5% of the radiolabel remained in the lungs. This is approximately a 3.5-fold  
13 greater proportion than that reported by Sun et al. (1984), possibly because smaller amounts of  
14 BaP adsorbed on the particles resulted in stronger binding or possibly because of differences  
15 between inhalation exposure and intratracheal exposure. At 3 days following administration,  
16 more than 50% of the radioactivity remained in the lungs, nearly 30% had been excreted into the  
17 feces, and the remainder was distributed throughout the body. Experiments using rats with  
18 cannulated bile ducts showed that approximately 10% of the administered radioactivity appeared  
19 in the bile over a 10-h period and that less than 5% of the radioactivity entered the feces via  
20 mucociliary transport. Results of these studies showed that when organics are adsorbed to DPM  
21 the retention of organics in the lungs is increased considerably. Because retention time is very  
22 short following exposure to pure compounds not bound to particles, it can be concluded that the  
23 increased retention time is primarily the result of continued binding to DPM. The detection of  
24 labeled compounds in blood, systemic organs, urine, and bile as well as the trachea, however,  
25 provides evidence that at least some of the organics are eluted from the particles following  
26 deposition in the lungs and would not be available as a carcinogenic dose to the lung. As  
27 discussed in Section 3.6.3, most of the organics eluted from particles deposited in the alveolar  
28 region, especially PAHs, are predicted to rapidly enter the bloodstream and thus not to contribute  
29 to potential induction of lung cancer.

### 31 **3.5.1.2. Studies in Occupationally Exposed Humans**

32 DNA adducts in the lungs of experimental animals exposed to diesel exhaust have been  
33 measured in a number of animal experiments (World Health Organization, 1996). Such studies,  
34 however, provide limited information regarding bioavailability of organics, as positive results may  
35 well have been related to factors associated with lung particle overload, a circumstance reported  
36 by Bond et al. (1990), who found carbon black, a substance virtually devoid of organics, to induce

1 DNA adducts in rats at lung overload doses. These authors showed that levels of DNA adducts  
2 present in pulmonary type II cells from the lungs of rats (n=15) exposed to equivalent conditions  
3 of either carbon black or diesel exhaust (each at 6.2 mg/m<sup>3</sup>) were nearly the same and 4- to 5-fold  
4 more than air-exposed controls. This similarity was noted despite a difference of nearly three  
5 orders of magnitude in solvent-extractable organic content between diesel exhaust (30%) and  
6 carbon black (0.04%). None of the diesel exhaust or carbon black adducts comigrated with  
7 BPDE (BaP diol epoxide).

8 On the other hand, DNA adduct formation and/or mutations in blood cells following  
9 exposure to DPM, especially at levels insufficient to induce lung overload, can be presumed to be  
10 the result of organics diffusing into the blood. Hemminki et al. (1994) reported increased levels  
11 of DNA adducts in lymphocytes of bus maintenance and truck terminal workers. Österholm et al.  
12 (1995) studied mutations at the hprt-locus of T-lymphocytes in bus maintenance workers.  
13 Although they were unable to identify clear-cut exposure-related differences in types of  
14 mutations, adduct formation was significantly increased in the exposed workers. Nielsen et al.  
15 (1996) reported significantly increased levels of lymphocyte DNA adducts, hydroxyvaline adducts  
16 in hemoglobin, and 1-hydroxypyrene in urine of garage workers exposed to diesel exhaust.

### 18 **3.5.2. In Vitro Studies**

#### 19 **3.5.2.1. Extraction of Diesel Particle-Associated Organics by Biological Fluids**

20 In vitro extraction of mutagenic organics by biological fluids can be estimated by  
21 measurement of mutagenic activity in the particular fluid. Using this approach, Brooks et al.  
22 (1981) reported extraction efficiencies of only 3% to 10% that of dichloromethane following  
23 DPM incubation in lavage fluid, serum, saline, albumin, or dipalmitoyl lecithin. Moreover,  
24 extraction efficiency did not increase with incubation time up to 120 h. Similar findings were  
25 reported by King et al. (1981), who also reported that lung lavage fluid and lung cytosol fluid  
26 extracts of DPM were not mutagenic. Serum extracts of DPM did exhibit some mutagenic  
27 activity, but considerably less than that of organic solvent extracts. Furthermore, the mutagenic  
28 activity of the solvent extract was significantly reduced when combined with serum or lung  
29 cytosol fluid, suggesting protein binding or biotransformation of the mutagenic components. Siak  
30 et al. (1980) assessed the mutagenicity of material extracted from DPM by bovine serum albumin  
31 in solution, simulated lung surfactant, fetal calf serum (FCS), and physiological saline. Only FCS  
32 was found to extract some mutagenic activity from the DPM. Keane et al. (1991), however,  
33 reported positive effects for mutagenicity in *Salmonella* and sister chromatid exchange in V79  
34 cells exclusively in the supernatant fraction of DPM dispersed in aqueous mixtures of dipalmitoyl  
35 phosphatidyl choline, a major component of pulmonary surfactant, indicating that pulmonary  
36 surfactant components can extract active components of DPM and result in bioavailability.

1 The ability of biological fluids to extract organics in vitro and their effectiveness in vivo  
2 remains equivocal because of the character of the particular fluid. For example, extracellular lung  
3 fluid is a complex mixture of constituents that undoubtedly have a broad range of hydrophobicity  
4 (George and Hook, 1984; Wright and Clements, 1987), which is fundamentally different from  
5 serum in terms of chemical composition (Gurley et al., 1988). Moreover, assessments of the  
6 ability of lavage fluids, which actually represent substantially diluted extracellular lung fluid, to  
7 extract mutagenic activity from DPM clearly do not reflect the in vivo condition. Finally, except  
8 under very high exposure concentrations, few particles escape phagocytosis and possible  
9 intracellular extraction. In this respect, Hiura et al. (1999) have shown that whole DPM, but not  
10 carbon black or diesel particles devoid of organics, induces apoptosis, apparently through  
11 generation of oxygen radicals. This study implicates organic compounds present on DPM. It also  
12 indicates the bioavailability of organics for generation of radicals from reaction with particle-  
13 associated organics or following elution from DPM.

#### 14 15 **3.5.2.2. *Extraction of DPM-Associated Organics by Lung Cells and Cellular Components***

16 A more likely means by which organics may be extracted from DPM and metabolized in  
17 the lung is either through particle dissolution or extraction of organics from the particle surface  
18 within the phagolysosomes of AMs and other lung cells. This mechanism presupposes that the  
19 particles are internalized. Specific details about the physicochemical conditions of the  
20 intraphagolysosomal environment, where particle dissolution in AMs presumably occurs in vivo,  
21 have not been well characterized. It is known that phagolysosomes constitute an acidic (pH 4 to  
22 5) compartment in macrophages (Nilsen et al., 1988; Ohkuma and Poole, 1978). The relatively  
23 low pH in the phagolysosomes has been associated with the dissolution of some types of inorganic  
24 particles (some metals) by macrophages (Marafante et al., 1987; Lundborg et al., 1984), but few  
25 studies provide quantitative information concerning how organics from DPM may be extracted in  
26 the phagolysosomes (Bond et al., 1983). Whatever the mechanism, assuming elution occurs, the  
27 end result is a prolonged exposure of the respiratory epithelium to DPM organics, which include  
28 low concentrations of carcinogenic agents such as PAH.

29 Early studies by King et al. (1981) found that when pulmonary alveolar macrophages were  
30 incubated with DPM, amounts of organic compounds and mutagenic activity decreased  
31 measurably from the amount originally associated with the particles, suggesting that organics  
32 were removed from the phagocytized particles. Leung et al. (1988) studied the ability of rat lung  
33 and liver microsomes to facilitate transfer and metabolism of BaP from diesel particles. <sup>14</sup>C-BaP  
34 coated diesel particles, previously extracted to remove the original organics, were incubated  
35 directly with liver or lung microsomes. About 3% of the particle-adsorbed BaP was transferred to  
36 the lung microsomes within 2 h. Of this amount about 1.5% was metabolized, for a total of about

1 0.05% of the BaP originally adsorbed to the DPM. Although transformation is slow, the long  
2 retention of particles, including DPM, in humans may cause the fraction eluted and metabolized to  
3 be considerably higher than this figure.

4 In analyzing phagolysosomal dissolution of various ions from particles in the lungs of  
5 Syrian golden hamsters, however, Godleski et al. (1988) demonstrated that solubilization did not  
6 necessarily result in clearance of the ions (and therefore general bioavailability) in that binding of  
7 the solubilized components to cellular and extracellular structures occurred. It is reasonable to  
8 assume that phagocytized DPM particles may be subject to similar processes and that these  
9 processes would be important in determining the rate of bioavailability of the particle-bound  
10 constituents of DPM.

11 Alveolar macrophages or macrophage cell lines that were exposed to high concentrations  
12 of DPM in vitro were observed to undergo apoptosis, which was attributed to the generation of  
13 reactive oxygen radicals (ROR) (Hiura et al. 1999). Further experimentation showed that DPM  
14 with the organic constituents extracted was no longer able to induce apoptosis or generate ROR.  
15 The organic extracts alone, however, were able to induce apoptosis as well as the formation of  
16 stress-activated protein kinases that play definitive roles in cellular apoptotic pathways. The  
17 injurious effects of nonextracted DPM or of DPM extracts were observed to be reversible by the  
18 antioxidant radical scavenger N-acetyl cysteine. These data suggest strongly that, at least at high  
19 concentrations of DPM, the organic constituents contained on DPM play a central role in cellular  
20 toxicity and that this toxicity may be attributable to the generation of ROR.

### 21 22 **3.5.3. Modeling Studies**

23 Gerde et al. (1991a,b) described a model simulating the effect of particle aggregation and  
24 PAH content on the rate of PAH release in the lung. According to this model, particle  
25 aggregation will occur with high exposure concentrations, resulting in a slow release of PAHs and  
26 prolonged exposure to surrounding tissues. However, large aggregates of particles are unlikely to  
27 form at doses typical of human exposures. Inhaled particles, at low concentrations, are more  
28 likely to deposit and react with surrounding lung medium without interference from other  
29 particles. The model predicts that under low-dose exposure conditions, more typical in  
30 humans, particle-associated organics will be released more rapidly from the particles because they  
31 are not aggregated. Output from this model suggests strongly that sustained exposure of target  
32 tissues to PAHs will result from repeated exposures, not from increased retention due to  
33 association of PAHs with carrier particles. This distinction is important because at low doses  
34 PAH exposure and lung tumor formation would be predicted to occur at sites of deposition rather  
35 than retention, as occurs with high doses.

1 The site of release of PAHs influences effective dose to the lungs because, as noted  
2 previously, at least some free organic compounds deposited in the lungs are rapidly absorbed into  
3 the bloodstream. Gerde et al. (1991b) predicted PAHs would be retained in the alveoli less than 1  
4 min, whereas they may be retained in the conducting airways for hours. These predictions were  
5 based on an average diffusion distance to capillaries of only about 0.5  $\mu\text{m}$  in the alveoli, as  
6 compared to possibly greater than 50  $\mu\text{m}$  in the conducting airways such as the bronchi. An  
7 experimental study by Gerde et al. (1999) provided support for this prediction. Beagle dogs were  
8 exposed to  $^3\text{H}$ -BaP adsorbed on the carbonaceous core of DPM at a concentration of 15  $\mu\text{g}$   
9 BaP/gm particles. A rapidly eluting fraction from DPM deposited in the alveoli was adsorbed into  
10 the bloodstream and metabolized in the liver, whereas the rapidly eluting fraction from DPM  
11 deposited in the conducting airways was to a large extent retained and metabolized in situ in the  
12 airway epithelium. Thus, organics eluting from DPM depositing in the conducting airways (i.e.,  
13 the TB region) would have a basis for a longer residence time in the tissues (and for consequent  
14 biological activity) than would organics eluting from DPM depositing in the pulmonary  
15 parenchyma. And, given the same overall deposited dose of DPM to the total pulmonary system,  
16 a deposited dose with a higher proportion in the TB region would incur a higher probability of  
17 tissue interactions with any eluted organics. This may be the case when comparing regional doses  
18 of DPM to humans as compared to rats for two reasons. First, one deposition model (Freijer et  
19 al., 1999) projects that for air concentrations of DPM at either 0.1 or 1.0  $\text{mg}/\text{m}^3$ , a higher  
20 proportion of the total DPM dose to the pulmonary system would be deposited in the TB area for  
21 humans at 31% (TB/Total; 0.098 / 0.318) than for rats at only 16% (0.04 / 0.205). Second,  
22 comparative morphometry data of DPM from chronically exposed rats and primates showed  
23 higher levels of DPM adjacent to conducting airways in primates (i.e., the interstitium of the  
24 respiratory bronchioles) than were present in parallel regions in the rat (interstitium of the alveolar  
25 ducts) (Nikula et al., 1997a,b). The focal nature of this deposition could give rise to localized  
26 high concentrations of any organics eluted.

27 Overall, the results of studies presented in Section 3.6 provide evidence that at least some  
28 of the organic matter adsorbed to DPM deposited in the respiratory tract is eluted. The  
29 percentage taken up and metabolized to an active form by target cells is, however, uncertain.  
30 Organics eluted from particles deposited in alveoli are likely to rapidly enter the bloodstream via  
31 translocation across endothelial cells, where they may undergo metabolism by enzymes such as  
32 cytochromes P-450 that are capable of producing reactive species. Organics eluted from particles  
33 deposited in the conducting airways (the bronchioles, bronchi, and trachea) may also undergo  
34 metabolism in other cell types such as the Clara cells with constituent or inducible cytochrome P-  
35 450 species. Risk of harmful effects for particles deposited in the conducting airways is predicted  
36 to be greater because solubilized organic compounds will be retained in the thicker tissue longer,

1 allowing for metabolism by epithelial cells lining the airways. Furthermore, since some deposition  
2 conducting airways occurs primarily at bifurcations, localized higher concentrations may occur.  
3 At present, unfortunately, the available data are insufficient to accurately model the effective dose  
4 of organics in the respiratory tract of humans or animals exposed to DPM.

#### 5 6 **3.5.4. Bioavailability/Deposition of Organics**

7 Using the data presented by Xu and Yu (1987), it is possible to calculate the total mass of  
8 DPM, as well as the total organic mass and specific carcinogenic PAHs deposited in the lungs of  
9 an individual exposed to DPM. For example, the annual deposition of DPM in the lungs of an  
10 individual exposed continuously to  $1 \mu\text{g}/\text{m}^3$  DPM can be estimated to be about  $420 \mu\text{g}$  based on  
11 total lung volume (see Table 3-1). About 0.7% of particle mass consists of PAHs (see Section  
12 2.2.6.2, Chapter 2) for a total of  $2.94 \mu\text{g}$ . Of this amount, the deposited mass of nitro-polycyclic  
13 aromatic compounds, based on data by Campbell and Lee (1984), would equal 37 ng, while the  
14 deposited mass of 7 PAHs that tested positive in cancer bioassays (U.S. EPA, 1993), and  
15 measured by Tong and Karasek (1984), would range from 0.16 to  $0.35 \mu\text{g}$ . Exercises similar to  
16 this have been carried out by others, e.g., Valberg and Watson (1999). However, the possibility  
17 that high concentrations of DPM may result in localized areas of deposition (such as the  
18 conducting airways), the fact that human exposures may be considerably greater than those  
19 presupposed in the exercise (e.g.,  $1 \mu\text{g}/\text{m}^3$ ), the nature of the assays (i.e., in vitro in Chapter 4 vs.  
20 actual inhalation exposures), and the findings that DNA adducts may result from other known  
21 noncarcinogens such as carbon black (Bond et al., 1990) make the interpretation of such exercises  
22 problematic and their meaning unclear.

### 23 24 **3.6. MODELING THE DEPOSITION AND CLEARANCE OF PARTICLES IN THE** 25 **RESPIRATORY TRACT**

#### 26 **3.6.1. Introduction**

27 The biological effects of inhaled particles are a function of their disposition, i.e., their  
28 deposition and clearance. This, in turn, depends on their patterns of deposition (i.e., the sites  
29 within which particles initially come into contact with airway epithelial surfaces and the amount  
30 removed from the inhaled air at these sites) and clearance (i.e., the rates and routes by which  
31 deposited materials are removed from the respiratory tract). Removal of deposited materials  
32 involves the competing processes of macrophage-mediated clearance and dissolution-absorption.  
33 Over the years, mathematical models for predicting deposition, clearance and, ultimately,  
34 retention of particles in the respiratory tract have been developed. Such models help interpret  
35 experimental data and can be used to make predictions of deposition for cases where data are not

1 available. A review of various mathematical deposition models was given by Morrow and Yu  
2 (1993) and in U.S. EPA (1996).

3 Currently available data for long-term inhalation exposures to poorly soluble particles  
4 (e.g., TiO<sub>2</sub>, carbon black, and DPM) show that pulmonary retention and clearance of these  
5 particles are not adequately described by simple first-order kinetics and a single compartment  
6 representing the alveolar macrophage particle burden. Several investigators have developed  
7 models for deposition, transport, and clearance of poorly soluble particulate matter in the lungs.  
8 All of these models identify various compartments and associated transport rates, but empirically  
9 derived data are not available to substantiate many of the assumptions made in these models.

## 10 11 **3.6.2. Dosimetry Models for DPM**

### 12 **3.6.2.1. Introduction**

13 The extrapolation of toxicological results from laboratory animals to humans, the goal of  
14 this chapter, requires the use of dosimetry models for both species that include, first, the  
15 deposition of DPM in various regions of the respiratory tract, and second, the transport and  
16 clearance of the particles, including adsorbed constituents, from their deposited sites. Therefore  
17 the ideal model structure would incorporate both deposition and clearance in animals and humans.

18 Deposition of particles in the respiratory tract, as described above, can be by impaction,  
19 sedimentation, interception, and diffusion, with the contribution from each mechanism a function  
20 of particle size, lung structure, and size and breathing parameters. Because of the size of diesel  
21 particles, under normal breathing conditions most of this deposition takes place by diffusion, and  
22 the fraction of the inhaled mass that is deposited in the thoracic region (i.e., TB plus A regions) is  
23 substantially similar for rats and humans.

24 Among deposition models that include aspects of lung structure and breathing dynamics,  
25 the most widely used have been typical-path or single-path models (Yu, 1978; Yu and Diu, 1983).  
26 The single-path models are based on an idealized symmetric geometry of the lung, assuming  
27 regular dichotomous branching of the airways and alveolar ducts (Weibel, 1963). They lead to  
28 modeling the deposition in an average regional sense for a given lung depth. Although the lower  
29 airways of the lung may be reasonably characterized by such a symmetric representation, there are  
30 major asymmetries in the upper airways of the tracheobronchial tree that in turn lead to different  
31 apportionment of airflow and particulate burden to the different lung lobes. The rat lung structure  
32 is highly asymmetric because of its monopodial nature, leading to significant errors in a single-  
33 path description. This is rectified in the multiple-path model of the lung, which incorporates  
34 asymmetry and heterogeneity in lung branching structure and calculates deposition at the  
35 individual airway level. This model has been developed for the rat lung (Anjilvel and Asgharian,  
36 1995; Freijer et al., 1999) and, in a limited fashion because of insufficient morphometric data, for

1 the human lung (Subramaniam et al., 1998; Yeh and Schum, 1980). Such models are particularly  
2 relevant for fine and ultrafine particles such as occur in DPM. However, models for clearance  
3 have not yet been implemented in conjunction with the use of the multiple-path model.

4 Clearance of particles in the respiratory tract takes place (1) by mechanical processes:  
5 mucociliary transport in the ciliated conducting airways and macrophage phagocytosis and  
6 migration in the nonciliated airways, and (2) by dissolution. The removal of material such as the  
7 carbonaceous core of DPM is largely by mechanical clearance, whereas the clearance of the  
8 organics adsorbed onto the carbon core is principally by dissolution.

9 Several clearance models currently exist, some specifically for humans and others specific  
10 for laboratory animals. They differ significantly in the level of physiological detail that is captured  
11 in the model and in the uncertainties associated with the values of the parameters used. All of  
12 these models identify various compartments and associated transport rates, but empirically derived  
13 data are not available to validate many of the assumptions made in the models. A review of the  
14 principal human and animal deposition/clearance models, including candidate models for use in  
15 animal-to-human extrapolation in this assessment, are considered below.

#### 16 17 **3.6.2.2. Human Models**

18 The International Commission on Radiological Protection (ICRP) recommends specific  
19 mathematical dosimetry models as a means to calculate the mass deposition and retention by  
20 different parts of the human respiratory tract and, if needed, tissues beyond the respiratory tract.  
21 The latest ICRP-recommended model, ICRP66 (1994), considers the human respiratory tract as  
22 four general anatomical regions: the ET region, which is divided into two subregions; the TB  
23 region, which is also subdivided into two regions; and the gas-exchange tissues, which are further  
24 defined as the alveolar-interstitial (AI) region but are exactly comparable to the pulmonary or  
25 A region. The fourth region is the lymph nodes. Deposition in the four regions is given as a  
26 function of particle size with two different types of particle size parameters: activity median  
27 thermodynamic diameter (AMTD) for deposition of particles ranging in size from 0.0005 to 1.0  
28  $\mu\text{m}$  and the activity median aerodynamic diameter (AMAD) for deposition of particles from 0.1 to  
29  $100\mu\text{m}$ . Reference values of regional deposition are provided and guidance is given for  
30 extrapolating to specific individuals and populations under different levels of activity. This model  
31 also includes consideration of particle inhalability, a measure of the degree to which particles can  
32 enter the respiratory tract and be available for deposition. After deposition occurs in a given  
33 region, two different intrinsic clearance processes act competitively on the deposited particles:  
34 particle transport, including mucociliary clearance from the respiratory tract and physical  
35 clearance of particles to the regional lymph nodes; and absorption, including movement of  
36 material to blood and both dissolution-absorption and transport of ultrafine particles. Rates of

1 particle clearance derived from studies with human subjects are assumed to be the same for all  
2 types of particles. The ICRP model provides average concentration or average number values on  
3 a regional basis, i.e., mass or number deposited or retained in the ET, TB, or A regions.  
4 Additionally, while the ICRP66 model was developed primarily for use with airborne radioactive  
5 particles and gases in humans, its use for describing the dosimetry of inhaled mass of  
6 nonradioactive substances in humans is also appropriate.

7 An alternative new human respiratory tract dosimetry model that developed concurrently  
8 with the new ICRP model is being proposed by the National Council on Radiation Protection  
9 (NCRP). This model was described in outline by Phalen et al. (1991). As with the 1994 ICRP66  
10 model (ICRP66, 1994), the proposed NCRP model addresses (1) inhalability of particles, (2) new  
11 subregions of the respiratory tract, (3) dissolution-absorption as an important aspect of the  
12 model, and (4) body size (and age). The proposed NCRP model defines the respiratory tract in  
13 terms of a naso-oro-pharyngo-laryngeal (NOPL) region, a TB region, a pulmonary (P) region,  
14 and the lung-associated lymph nodes (LN). The rates of dissolution-absorption of particles and  
15 their constituents are derived from clearance data from humans and laboratory animals. The  
16 effect of body growth on particle deposition is also considered in the model, but particle clearance  
17 rates are assumed to be independent of age. The NCRP model does not consider the fate of  
18 inhaled materials after they leave the respiratory tract. Although the proposed NCRP model  
19 describes respiratory tract deposition, clearance, and dosimetry for radioactive substances inhaled  
20 by humans, the model can also be used for evaluating inhalation exposures to all types of particles.  
21 Graphical outputs of regional deposition fractions from both the ICRP66 (1994) and draft NCRP  
22 models presented in U.S. EPA (1996) indicate approximately 15% would be deposited in the  
23 alveolar region at the MMAD of DPM, 0.2  $\mu\text{m}$ .

### 24 25 **3.6.2.3. *Animal Models***

26 Strom et al. (1988) developed a multicompartamental model for particle retention that  
27 partitioned the alveolar region into two compartments on the basis of the physiology of clearance.  
28 The alveolar region has a separate compartment for sequestered macrophages, corresponding to  
29 phagocytic macrophages that are heavily laden with particles and clustered, and consequently  
30 have significantly lowered mobility. The model has the following compartments:

31 (1) tracheobronchial tree, (2) free particulate on the alveolar surface, (3) mobile phagocytic  
32 alveolar macrophages, (4) sequestered particle-laden alveolar macrophages, (5) regional lymph  
33 nodes, and (6) gastrointestinal tract. The model is based on mass-dependent clearance (the rate  
34 coefficients reflect this relationship), which dictates sequestration of particles and their eventual  
35 transfer to the lymph nodes. The transport rates between various compartments were obtained by  
36 fitting the calculated results to lung and lymph node burden experimental data for both exposure

1 and postexposure periods. Because the number of fitted parameters was large, the model is not  
2 likely to provide unique solutions that would simulate experimental data from various sources and  
3 for different exposure scenarios. For the same reason, it is not readily possible to use this model  
4 for extrapolating to humans.

5 Stöber and co-workers have worked extensively in developing models for estimating  
6 retention and clearance of relatively insoluble respirable particles (as DPM) in the lung. Their  
7 most recent work (1994), a revised version of the POCK model, is a rigorous attempt to  
8 incorporate most of the physiologically known aspects of alveolar clearance and retention of  
9 inhaled relatively insoluble particles. Their multicompartmental kinetics model has five  
10 subcompartments. The transfer of particles between any of the compartments within the alveolar  
11 region is macrophage mediated. There are two compartments that receive particles cleared from  
12 the alveolar regions: the TB tract and the lymphatic system. The macrophage pool includes both  
13 mobile and particle-laden immobilized macrophages. The model assumes a constant maximum  
14 volume capacity of the macrophages for particle uptake and a material-dependent critical  
15 macrophage load that results in total loss of macrophage mobility. Sequestration of those  
16 macrophages heavily loaded with a particle burden close to a volume load capacity is treated in a  
17 sophisticated manner by approximating the particle load distribution in the macrophages. The  
18 macrophage pool is compartmentalized in terms of numbers of macrophages that are subject to  
19 discrete particle load intervals. Upon macrophage death, the phagocytized particle is released  
20 back to the alveolar surface; thus phagocytic particle collection competes to some extent with this  
21 release back to the alveolar surface. This recycled particle load is also divided into particle  
22 clusters of size intervals defining a cluster size distribution on the alveolar surface. The model  
23 yields a time-dependent frequency distribution of loaded macrophages that is sensitive to both  
24 exposure and recovery periods in inhalation studies.

25 The POCK model also emphasizes the importance of interstitial burden in the particle  
26 overload phenomenon and indicates that particle overload is a function of a massive increase in  
27 particle burden of the interstitial space rather than total burden of the macrophage pool. The  
28 relevance of the increased particle burden in the interstitial space lies with the fact that this  
29 compartmental burden is not available for macrophage-mediated clearance and, therefore, persists  
30 even after cessation of exposure.

31 Although the POCK model is the most sophisticated in the physiological complexity it  
32 introduces, it suffers from a major disadvantage. Experimental retention studies provide data only  
33 on total alveolar and lymph node mass burdens of the particles as a function of time. The relative  
34 fraction of the deposition between the alveolar subcompartments in the Stöber model therefore  
35 cannot be obtained experimentally; the model thus uses a large number of parameters that are  
36 simultaneously fit to experimental data. Although the model predictions are tenable, experimental

1 data are not currently available to substantiate the proposed compartmental burdens or the  
2 transfer rates associated with these compartments. Thus, overparameterization in the model leads  
3 to the possibility that the model may not provide a unique solution that may be used for a variety  
4 of exposure scenarios, and for the same reason, cannot be used for extrapolation to humans.  
5 Stöber et al. have not developed an equivalent model for humans; therefore the use of their model  
6 in our risk assessment for diesel is not attempted.

#### 8 **3.6.2.4. Combined Models (for Interspecies Extrapolation)**

9 Currently available data for long-term inhalation exposures to poorly soluble particles  
10 (e.g., TiO<sub>2</sub>, carbon black, and DPM) show that pulmonary retention and clearance of these  
11 particles are not adequately described by simple first-order kinetics and a single compartment  
12 representing the alveolar macrophage particle burden. A two-compartment lung model that could  
13 be applied to both humans and animals was developed by Smith (1985) and includes alveolar and  
14 interstitial compartments. For uptake and clearance of particles by alveolar surface macrophages  
15 and interstitial encapsulation of particles (i.e., quartz dust), available experimental data show that  
16 the rate-controlling functions followed Michaelis-Menton type kinetics, whereas other processes  
17 affecting particle transfer are assumed to be linear. The model was used in an attempt to estimate  
18 interstitial dust and fibrosis levels among a group of 171 silicon carbide workers; the levels were  
19 then compared with evidence of fibrosis from chest radiographs. A significant correlation was  
20 found between estimated fibrosis and profusion of opacities on the radiographs. This model  
21 provides as many as seven different rate constants derived by various estimations and under  
22 various conditions from both animal and human sources. The model was intended for estimation  
23 of generalized dust described only as respirable without any other regard to sizing for establishing  
24 the various particle-related rate constants. As most of the described functions could not be  
25 validated with experimental data, the applicability of this model, especially for particulates in the  
26 size range of DPM, was unclear.

27 Yu et al. (1991; also reported as Yu and Yoon, 1990) have developed a three-  
28 compartment lung model that consists of tracheobronchial (T), alveolar (A), and lymph node (L)  
29 compartments (Appendix A, Figure A-1) and, in addition, considered filtration by a  
30 nasopharyngeal or head (H) compartment. Absorption by the blood (B) and gastrointestinal (G)  
31 compartments was also considered. Although the treatment of alveolar clearance is  
32 physiologically less sophisticated than that of the Stöber et al. model, the Yu model provides a  
33 more comprehensive treatment of clearance by including systemic compartments and the head,  
34 and including the clearance of the organic components of DPM in addition to the relatively  
35 insoluble carbon core.

1           The tracheobronchial compartment is important for short-term considerations, whereas  
2 long-term clearance takes place via the alveolar compartment. In contrast to the Stöber and  
3 Strom approaches, the macrophage compartment in the Yu model contains all of the phagocytized  
4 particles; that is, there is no separate (and hypothetical) sequestered macrophage  
5 subcompartment. Instead, in order to progress beyond the classical human ICRP66 retention  
6 model, Yu has addressed the impairment of long-term clearance (the overload effect) by using a  
7 set of variable transport rates for clearance from the alveolar region as a function of the mass of  
8 DPM in the alveolar compartment. A functional relationship for this was derived mathematically  
9 (Yu et al., 1989) based upon Morrow's hypothesis for the macrophage overload effect discussed  
10 earlier in the section on pulmonary overload. The extent of the impairment depends on the initial  
11 particle burden, with greater particulate concentration leading to slower clearance.

12           Within this model DPM is treated as being composed of three material components: a  
13 relatively insoluble carbonaceous core, slowly cleared organics (10% particle mass), and fast-  
14 cleared organics (10% particle mass). Such a partitioning of organics was based on observations  
15 that the retention of particle-associated organics in lungs shows a biphasic decay curve (Sun et al.,  
16 1984; Bond et al., 1986). For any compartment, each of these components has a different  
17 transport rate. The total alveolar clearance rate of each material component is the sum of  
18 clearance rates of that material from the alveolar to the tracheobronchial, lymph, and blood  
19 compartments. In the Strom and Stöber models discussed above, the clearance kinetics of DPM  
20 were assumed to be entirely dictated by those of the relatively insoluble carbonaceous core. For  
21 those organic compounds that get dissociated from the carbon core, clearance rates are likely to  
22 be very different, and some of these compounds may be metabolized in the pulmonary tissue or be  
23 absorbed by blood.

24           The transport rates for the three components were derived from experimental data for rats  
25 using several approximations. The transport rates for the carbonaceous core and the two organic  
26 components were derived by fitting to data from separate experiments. Lung and lymph node  
27 burdens from the experiment of Strom et al. (1988) were used to determine the transport rate of  
28 the carbonaceous core. The Yu model incorporates the impairment of clearance by including a  
29 mass dependency in the transport rate. This mass dependency is easily extracted because the  
30 animals in the experiment were killed over varying periods following the end of exposure.

31           It was assumed that the transport rates from the alveolar and lymph compartments to the  
32 blood were equal and independent of the particulate mass in the alveolar region. The clearance  
33 rates of particle-associated organics for rats were derived from the retention data of Sun et al.  
34 (1984) for benzo[a]pyrene and the data of Bond et al. (1986) for nitropyrene adsorbed on diesel  
35 particles.

1 In their model Yu et al. (1991) make two important assumptions to carry out the  
2 extrapolation in consideration of inadequate human data. First, the transport rates of organics in  
3 the DPM do not change across species. This is based upon lung clearance data of inhaled  
4 lipophilic compounds (Schanker et al., 1986), where the clearance was seen to be dependent on  
5 the lipid/water partition coefficient. In contrast, the transport rate of the carbonaceous core is  
6 considered to be significantly species dependent (Bailey et al., 1982). DPM clearance rate is  
7 determined by two terms in the model (see Equation A-82 in Appendix A). The first,  
8 corresponding to macrophage-mediated clearance, is a function of the lung burden and is assumed  
9 to vary significantly across species. The second term, a constant, corresponding to clearance by  
10 dissolution, is assumed to be species independent. The mass-dependent term for humans is  
11 assumed to vary in the same proportion as in rats under the same unit surface particulate dose.  
12 The extrapolation is then achieved by using the data of Bailey et al. (1982) for the low lung  
13 burden limit of the clearance rate. This value of 0.0017/day was lower than the rat value by a  
14 factor of 7.6. This is elaborated further in Appendix A. Other transport rates that have lung  
15 burden dependence are extrapolated in the same manner.

16 The Bailey et al. (1982) experiment, however, used fused monodisperse aluminosilicate  
17 particles of 1.9 and 6.1  $\mu\text{m}$  aerodynamic diameters. Yu and co-workers have used the longer of  
18 the half-times obtained in this experiment; in using such data for DPM 0.2  $\mu\text{m}$  in diameter, they  
19 have assumed the clearance of relatively insoluble particles to be independent of size over this  
20 range. This appears to be a reasonable assumption because the linear dimensions of an alveolar  
21 macrophage are significantly larger, roughly 10  $\mu\text{m}$  (Yu et al., 1996). However, Snipes (1979)  
22 has reported a clearance rate (converted here from half-time values) of 0.0022/day for 1 and 2  $\mu\text{m}$   
23 particles but a higher value of 0.0039/day for 0.4  $\mu\text{m}$  particles. In the absence of reliable data for  
24 0.2  $\mu\text{m}$  particles, clearance rate pertaining to this much larger particle size is being used.  
25 Although such a choice may underestimate the correct clearance rate for DPM, the resulting error  
26 in the output (i.e., a human equivalent concentration) is likely to be only more protective of  
27 human health. Long-term clearance rates for particle sizes more comparable to DPM are  
28 available, e.g., iron oxide and polystyrene spheres (Waite and Ramsden, 1971; Jammet et al.,  
29 1978), but these data show a large range in the values obtained for half-lives or are based upon a  
30 very small number of trials, and therefore compare unfavorably with the quality of data from the  
31 Bailey experiment.

32 The deposition fractions of particulate matter in the pulmonary and tracheobronchial  
33 regions of the human lung remain relatively unchanged over the particle size range between  
34 0.2 and 1.0  $\mu\text{m}$ , on the basis of the analysis done with the ICRP66 (1994) model as documented  
35 in the PMCD (U.S. EPA, 1996). As the clearance of relatively insoluble particles is also likely to  
36 remain the same over this range, the dosimetry results in this report for the carbonaceous core

1 component of DPM could also be extended to other particles in this size range within the PM<sub>2.5</sub>.  
2 For respirable particles with diameters larger than this range, e.g., between 1.0 and 3.5 μm, the  
3 extent of the fraction deposited in the pulmonary region is unclear. Results from the ICRP66  
4 (1994) model predict little change in human deposition for this diameter range, whereas the earlier  
5 model of Yu and Diu (1983) predicts a significant increase. It is therefore unclear if either model  
6 would be applicable for particles in this range without changing the value for the deposition  
7 fractions. As mentioned above, however, regional deposition fractions from both the ICRP66  
8 (1994) and draft NCRP models presented in U.S. EPA (1996) indicate approximately 15% would  
9 be deposited in the alveolar region at the MMAD of DPM, 0.2 μm. These values compare  
10 favorably with the human alveolar deposition in humans specific for DPM, which has been  
11 estimated with the Yu model to be 7% to 13% (Yu and Xu, 1986).

12 Although there was good agreement between experimental and modeled results, this  
13 agreement follows a circular logic (as adequately pointed out by Yu and Yoon [1990]) because  
14 the same experimental data that figured into the derivation of transport rates were used in the  
15 model. Nevertheless, even though this agreement is not a validation, it provides an important  
16 consistency check on the model. Further experimental data and policy definitions on what  
17 constitutes validation would be necessary for a more formal validation.

18 The model showed that at low lung burdens, alveolar clearance is dominated by  
19 mucociliary transport to the tracheobronchial region, and at high lung burdens, clearance is  
20 dominated by transport to the lymphatic system. The head and tracheobronchial compartments  
21 showed quick clearance of DPM by mucociliary transport and dissolution. Lung burdens of both  
22 the carbonaceous core and organics were found to be greater in humans than in rats for similar  
23 periods of exposure.

24 The Yu and Yoon (1990) version of the model provides a parametric study of the  
25 dosimetry model, examining variation over a range of exposure concentrations, breathing  
26 scenarios, and ventilation parameters; particle mass median aerodynamic diameters; and geometric  
27 standard deviations of the aerosol size distribution. It examines how lung burden varies with age  
28 for exposure over a lifespan, provides dosimetry extrapolations to children, and examines changes  
29 in lung burden with lung volume. The results showed that children would exhibit more diminished  
30 alveolar clearance of DPM at high lung burden than adults when exposed to equal concentrations  
31 of DPM. These features make the model easy to use in risk assessment studies. The reader is  
32 referred to Appendix A for further details on the model and for analyses of the sensitivity of the  
33 model to change in parameter values.

34 The Yu model presents some uncertainties in addition to those discussed earlier in the  
35 context of particle size dependence of clearance rate. The reports of Yu and Yoon (1990) as well  
36 as Yu et al. (1991) underwent extensive peer review; we list below the most important among the

1 model uncertainties discussed by the review panel. The experimental data used by the Yu model  
2 for adsorbed organics used passively adsorbed radiolabeled compounds as surrogates for  
3 combustion-derived organics. These compounds may adhere differently to the carbon core than  
4 do those formed during combustion. Yu has estimated that slowly cleared organics represent 10%  
5 of the total particle mass; the actual figure could be substantially less; the reviewers estimate that  
6 the amount of tightly bound organics is probably only 0.1% to 0.25% of the particle mass.

7 The model was based upon the experimental data of Strom et al. (1988), where  
8 Fischer-344 rats were exposed to DPM at a concentration of 6.0 mg/m<sup>3</sup> for 20 h/day and 7  
9 days/week for periods ranging from 3 to 84 days. Such exposures lead to particle overload effects  
10 in rats, whereas human exposure patterns are usually to much lower levels at which overload will  
11 not occur. Parameters obtained by fitting to data under the conditions of the experimental  
12 scenario for rats may not be optimal for the human exposure and concentration of interest.

13 The extrapolation of retained dose from rats to humans assumed that the macrophage-  
14 mediated mechanical clearance of the DPM varies with the specific particulate dose to the alveolar  
15 surface in the same proportion in humans and in rats, whereas clearance rates by dissolution were  
16 assumed to be invariant across species. This assumption has not been validated.

17 It should also be noted that the Yu et al. (1991) model does not possess an interstitial  
18 compartment. The work of Nikula et al. (1997a,b) and of Kuempel (2000) provide compelling  
19 information on the significance of an extensive interstitialization process in primates and in humans.  
20 Kuempel (2000) developed a lung dosimetry model to describe the kinetics of particle clearance  
21 and retention in coal miners' lungs. Models with overloading of lung clearance, as observed in  
22 rodent studies, were found to be inadequate to describe the end-of-life lung dust burdens in those  
23 miners. The model that provided the best fit to the human data included a sequestration process  
24 representing the transfer of particles to the interstitium. These findings are consistent with a study  
25 showing reduced lung clearance of particles in retired coal miners (Freedman and Robinson,  
26 1988) and with studies showing increased retention of particles in the lung interstitium of humans  
27 and nonhuman primates compared to rodents exposed to coal dust and/or diesel exhaust (Nikula  
28 et al., 1997a,b). Because the Yu model has not been validated on human data and does not  
29 include an interstitial compartment, it is acknowledged that this model may therefore underpredict  
30 the lung dust burdens in humans exposed to occupational levels of dust. However, it is also not  
31 known whether the model based on coal miner data (Kuempel, 2000) would also describe the  
32 clearance and retention processes in the lungs of humans with exposures to particles at lower  
33 environmental concentrations, or to submicrometer particles such as diesel exhaust particulate.  
34 Further investigation of these issues is needed.

### 36 **3.6.2.5. Use of the Yu et al. (1991) Model for Interspecies Extrapolation**

1           In addressing the objectives of this chapter, i.e., consideration of what is known and  
2 applicable to DPM concerning particle disposition and the bioavailability of adsorbed organics on  
3 DPM, it is apparent that the database is considerable for both the processes involved in particle  
4 dosimetry and for DPM. This information makes the goal of predicting a human internal dose  
5 from animal data through a model utilizing this database both feasible and appropriate.

6           In their charge to EPA through “Science and Judgment in Risk Assessment” (NRC, 1995),  
7 the National Research Council opines that EPA should have principles for judging when and how  
8 to depart from default options. The extensive data presented in this chapter (including the model  
9 of Yu), their scientific validity, and the limitations of the current default procedures provide a  
10 basis for departing from the default options currently identified by the Agency for extrapolating  
11 from animals to humans. The default option of assuming external concentrations of DPM in  
12 animal studies as being representative of a human concentration (and an equivalent internal dose)  
13 is clearly not adequate given the vast differences in the basic processes of deposition and  
14 clearance between animals and humans documented by these data. Use of an alternate default  
15 option, the Agency’s dosimetric adjustment procedures for inhaled particles in animal-to-human  
16 scenarios (described in U.S. EPA, 1994), is also inadequate as only deposition is predicted and  
17 then only down to an MMAD of 0.5  $\mu\text{m}$ , whereas the MMAD of DPM is typically 0.2  $\mu\text{m}$  or  
18 smaller. Models have been described in this section that consider both deposition and retention  
19 specifically for DPM in both laboratory animals and in humans. These points provide justification  
20 for moving away from default options and utilizing the best scientific information available (i.e.,  
21 that integrated into deposition/clearance models) in performing the animal-to-human  
22 extrapolation.

23           Of the models evaluated in this chapter, that of Yu et al. (1991) is uniquely equipped to  
24 perform animal-to-human extrapolation for DPM. The model structure is parsimonious, with  
25 three lung compartments (tracheobronchial, pulmonary, lymph node). Design of the model  
26 incorporated both human and animal information, utilizing empirical clearance data from both rats  
27 and humans. In addition to DPM, this model considers deposition and clearance of two classes of  
28 organics adsorbed onto DPM. The model does have limitations, such as a lack of definitive  
29 information on variability of the results and absence of a lung compartment (interstitial) that could  
30 well be of importance to humans. It is, however, considered that the attributes considerably  
31 outweigh the detractions in choosing this model as a means to perform animal-to-human  
32 extrapolation for DPM.

### 33 34 **3.7. SUMMARY**

35           The most consistent historical measure of exposure for diesel exhaust is DPM in units of  
36  $\mu\text{g}$  or  $\text{mg particles}/\text{m}^3$ , with the underlying assumption that all components of diesel emissions

1 (e.g., organics in the form of volatilized liquids or gases) are present in proportion to the DPM  
2 mass. DPM is used as the basic dosimeter for effects from various scenarios such as chronic and  
3 acute exposures as well as for different endpoints such as irritation, fibrosis, or even cancer.  
4 There is, however, little evidence currently available to prove or refute DPM as being the most  
5 appropriate dosimeter.

6 DPM dose to the tissue is related to the extent of the deposition and clearance of DPM.  
7 DPM may deposit throughout the respiratory tract via sedimentation or diffusion, with the latter  
8 being prevalent in the alveolar region. Particles that deposit upon airway surfaces may be cleared  
9 from the respiratory tract completely or may be translocated to other sites by regionally distinct  
10 processes that can be categorized as either absorptive (i.e., dissolution) or nonabsorptive (i.e.,  
11 transport of intact particles via mucociliary transport). With poorly soluble particles such as  
12 DPM, clearance by dissolution is insignificant compared to the rate of clearance as an intact  
13 particle. Other mechanisms that can affect retention of DPM include endocytosis by alveolar  
14 lining cells and interstitialization, which lead to the accumulation of DPM in the interstitial  
15 compartment of the lung and subsequent translocation of DPM to lymph nodes; interstitialization  
16 of poorly soluble particles is prominent in primates and humans as compared to rodents. For  
17 poorly soluble particles such as DPM, species-dependent rate constants exist for the various  
18 clearance pathways that can be modified by factors such as respiratory tract disease.

19 In rats, prolonged exposure to high concentrations of particles may be associated with  
20 particle overload, a condition that is defined as the overwhelming of macrophage-  
21 mediated clearance by the deposition of particles at a rate exceeding the capacity of that clearance  
22 pathway. This condition seems to begin to occur in rats when the pulmonary dust burden exceeds  
23 about 1 mg particles/g lung tissue. On the other hand, there is no clear evidence for particle  
24 overload in humans. Macrophage-mediated clearance appears to be slower and perhaps less  
25 important in humans than in rats, and interstitialization of poorly soluble particulate matter may be  
26 of greater consequence in humans than in rats.

27 The degree of bioavailability of the organic fraction of DPM is still somewhat uncertain.  
28 However, reports of DNA alterations in occupationally exposed workers, as well as results of  
29 animal studies using radiolabeled organics deposited on DPM, indicate that at least a fraction of  
30 the organics present are eluted prior to particle clearance. Carcinogenic organics eluted in regions  
31 where diffusion may be a relatively long process, such as in the conducting airways vs the alveolar  
32 region, may remain in the lung long enough to be metabolized to an active form or to interact  
33 directly with vital cellular components. The current information suggests that DPM-associated  
34 organics could be involved in a carcinogenic process, although the quantitative data are far from  
35 adequate to make any firm conclusions.

1 Use of laboratory animal data in an assessment meant to be applied to humans obligates  
2 some form of interspecies extrapolation. Review and evaluation of the considerable, specific  
3 database in humans and animals on disposition of DPM, its adsorbed organics, and other poorly  
4 soluble particles led to the judgment that default options available for interspecies dosimetry  
5 adjustment could be set aside for more scientifically valid, DPM-specific processes. Refinement  
6 of this evaluation led to the identification and choice of the Yu et al. (1991) model to conduct  
7 interspecies extrapolation. This model has a three-compartment lung consisting of  
8 tracheobronchial, alveolar, and lymph node compartments. It treats DPM as being composed of  
9 the insoluble carbonaceous core, slowly cleared organics, and fast-cleared organics, and considers  
10 in an integrative manner the simultaneous processes of both deposition and clearance through  
11 empirical data derived from both laboratory animals and humans. Also, the model has some  
12 limited consideration of model variability in its outputs describing dose to the lung. Major  
13 assumptions made in this model include that transport rates of organics in DPM do not change  
14 across species and that the transport rate of the carbonaceous core is species dependent, with the  
15 clearance rate varying with the dose to the alveolar surface in the same proportion in humans as in  
16 rats. Limitations of the model include the lack of definitive information on variability and the lack  
17 of a biological compartment (the interstitium) that may be of consequence in humans. The basis  
18 of this model is to derive an internal dose from an external DPM concentration by utilizing  
19 species-specific physiological and pharmacokinetic parameters and, as such, is considered to have  
20 addressed the pharmacokinetic aspects of interspecies dosimetry. This aspect of the model  
21 addresses some of the critical data needs for the quantitative analysis of noncancer effects from  
22 DPM, the subject of Chapter 6.

23 As parallels have been drawn between DPM and  $PM_{2.5}$  in other chapters, it is perhaps  
24 appropriate to compare them also from the aspect of dosimetry. Obvious comparisons include the  
25 nature of the particle distribution, defined artificially for  $PM_{2.5}$  as compared with the thorough  
26 characterization of DPM for both MMAD (which, at around  $0.2\ \mu\text{m}$ , is typically more than an  
27 order of magnitude less than the  $PM_{2.5}$  cutoff) and geometric standard deviation. It is clear that a  
28 larger portion of  $PM_{2.5}$  particles than DPM would be above the aerodynamic equivalent diameter  
29 ( $d_{ae}$ ) of  $0.5\ \mu\text{m}$ , which is often considered as a boundary between diffusion and aerodynamic  
30 mechanisms of deposition. This would imply that a somewhat larger portion of DPM may pass on  
31 to the lower respiratory tract than would  $PM_{2.5}$ . Alveolar deposition in humans specific for DPM  
32 has been estimated with the Yu model to be 7%-13% (Yu and Xu, 1986). This fractional  
33 deposition may be compared to one calculated for  $PM_{2.5}$  and reported in U.S. EPA (1996a);  
34 assuming a MMAD of  $2.25\ \mu\text{m}$  and a geometric standard deviation of 2.4, a fractional alveolar  
35 deposition of 10.2% was reported. This value is within the range and quite comparable to that

- 1 obtained by Yu and Xu (1986), indicating that little difference may exist in alveolar deposition
- 2 between DPM and  $PM_{2.5}$ , at least for this assumed geometric standard deviation.

**Table 3-1. Predicted doses of inhaled DPM per minute based on total lung volume (M), total airway surface area (M<sub>1</sub>), or surface area in alveolar region (M<sub>2</sub>)**

| Species     | M<br>(10 <sup>-3</sup> μg/min/cm <sup>3</sup> ) | M <sub>1</sub><br>(10 <sup>-6</sup> μg/min/cm <sup>2</sup> ) | M <sub>2</sub><br>(10 <sup>-6</sup> μg/min/cm <sup>2</sup> ) |
|-------------|---|--|--|
| Hamster     | 3.548   | 3.088  | 2.382  |
| Fischer rat | 3.434   | 3.463  | 2.608  |
| Human       | 0.249   | 1.237  | 0.775  |

M =  $\frac{\text{mass DPM deposited in lung per minute}}{\text{total lung volume}}$

M<sub>1</sub> =  $\frac{\text{mass DPM deposited in lung per minute}}{\text{total airway surface area}}$

M<sub>2</sub> =  $\frac{\text{mass DPM deposited on the unciliated airways per minute}}{\text{surface area of the unciliated airways}}$

Based on the following conditions: (1) mass median aerodynamic diameter (MMAD) = 0.2 μm; geometric standard deviation (σ<sub>g</sub>) = 1.9; packing density (φ) = 0.3; and particle mass density (ρ) = 1.5 g/cm<sup>3</sup>; (2) particle concentration = 1 mg/m<sup>3</sup>; and (3) nose-breathing. For humans, total lung volume = 3200 cm<sup>3</sup>, total airway surface area = 633,000 cm<sup>2</sup>, surface area of the unciliated airways = 627,000 cm<sup>2</sup>.

Source: Xu and Yu, 1987.

**Table 3-2. Alveolar clearance in laboratory animals exposed to DPM**

| Species/sex             | Exposure technique  | Exposure duration                     | Particles mg/m <sup>3</sup> | Observed effects   | Reference                 |
|-------------------------|---|---------------------------------------|-----------------------------|--|---------------------------|
| Rats, F-344, M          | Nose only;<br>Radiolabeled DPM  | 40-45 min                             | 6                           | Four days after exposure, 40% of DPM eliminated by mucociliary clearance. Clearance from lower RT was in 2 phases. Rapid mucociliary ( $t_{1/2} = 1$ day); slower macrophage-mediated ( $t_{1/2} = 62$ days).  | Chan et al. (1981)        |
| Rats, F-344             | Whole body;<br>assessed effect<br>on clearance of<br><sup>67</sup> Ga <sub>2</sub> O <sub>3</sub> particles | 7 h/day<br>5 days/week<br>24 mo       | 0.35<br>3.5<br>7.1          | $\tau_1$ significantly higher with exposure to 7.1 mg/m <sup>3</sup> for 24 mo; $\tau_2$ significantly longer after exposure to 7.1 mg/m <sup>3</sup> for 6 mo and to 3.5 mg/m <sup>3</sup> for 18 mo.   | Wolff et al. (1986, 1987) |
| Rats                    | Whole body  | 19 h/day<br>5 days/week<br>2.5 years  | 4                           | Estimated alveolar deposition = 60 mg; particle burden caused lung overload. Estimated 6-15 mg particle-bound organics deposited.  | Heinrich et al. (1986)    |
| Rats, F-344, MF         | Whole body  | 7 h/day<br>5 days/week<br>18 mo       | 0.15<br>0.94<br>4.1         | Long-term clearance was $87 \pm 28$ and $99 \pm 8$ days for 0.15 and 0.94 mg/m <sup>3</sup> groups, respectively; $t_{1/2} = 165$ days for 4.1 mg/m <sup>3</sup> group.  | Griffis et al. (1983)     |
| Rats, F-344;            | Nose-only;<br>Radiolabeled <sup>14</sup> C  | 45 min<br>140 min                     | 7<br>2                      | Rats demonstrated 3 phases of clearance with $t_{1/2} = 1, 6,$ and 80 days, representing tracheobronchial, respiratory bronchioles, and alveolar clearance, respectively. Guinea pigs demonstrated negligible alveolar clearance from day 10 to 432.           | Lee et al. (1983)         |
| Guinea pigs,<br>Hartley |   | 45 min                                | 7                           |  |                           |
| Rats, F-344             |   | 20 h/day<br>7 days/week<br>7-112 days | 0.25<br>6                   | Monitored rats for a year. Proposed two clearance models. Clearance depends on initial particle burden; $t_{1/2}$ increases with higher exposure. Increases in $t_{1/2}$ indicate increasing impairment of AM mobility and transition into overload condition. | Chan et al. (1984)        |

RT = respiratory tract.

AM = alveolar macrophage.

 $\tau_1$  = clearance from primary, ciliated airways. $\tau_2$  = clearance from nonciliated passages.






Figure 3-1. Modeled deposition distribution patterns of inhaled diesel exhaust particles in the airways of different species. Generation 1-18 are TB; >18 are A.

Source: Xu and Yu, 1987.




**Figure 3-2. Modeled clearance of poorly soluble 4- $\mu\text{m}$  particles deposited in tracheobronchial and alveolar regions in humans.**

Source: Cuddihy and Yeh, 1986.




**Figure 3-3. Short-term thoracic clearance of inhaled particles as determined by model prediction and experimental measurement.**

Source: Cuddihy and Yeh, 1986 (from Stahlhofen et al., 1980).



**Figure 3-4. Clearance from lungs of rats of  $^{134}\text{Cs}$ -FAP fused aluminosilicate tracer particles inhaled after 24 months of diesel exhaust exposure at concentrations of 0 (control), 0.35 (low), 3.5 (medium), and 7.1 (high) mg DPM/m<sup>3</sup>.**

Source: Wolff et al., 1987.



**Figure 3-5. Lung burdens of DPM within rats exposed to 0.35 (low) (●), 3.5 (medium) (▲), and 7.1 (high) mg ppm/m<sup>3</sup> (■).**

Source: Wolff et al., 1987.

1 **3.8. REFERENCES**

2  
3 Adamson, IYR; Bowden, DH. (1978) Adaptive responses of the pulmonary macrophagic system to carbon: II.  
4 Morphologic studies. Lab Invest 38:430-438.  
5  
6 Adamson, IYR; Bowden, DH. (1981) Dose response of the pulmonary macrophagic system to various particulates  
7 and its relationship to transepithelial passage of free particles. Exp Lung Res 2:165-175.  
8  
9 Anjilvel, S; Asgharian, B. (1995) A multiple-path model of particle deposition in the rat lung. Fundam Appl  
10 Toxicol 28:41-50.  
11  
12 Aronson, M. (1963) Bridge formation and cytoplasmic flow between phagocytic cells. J Exp Med 118:1083-1088.  
13  
14 Bailey, MR; Fry, FA; James, AC. (1982) The long-term clearance kinetics of insoluble particles from the human  
15 lung. Ann Occup Hyg 26:273-290.  
16  
17 Bailey, MR; Fry, FA; James, AC. (1985) Long-term retention of particles in the human respiratory tract. J  
18 Aerosol Sci 16:295-305.  
19  
20 Ball, LM; King, LC. (1985) Metabolism, mutagenicity, and activation of 1-nitropyrene *in vivo* and *in vitro*.  
21 Environ Int 11:355-361.  
22  
23 Battigelli, MC; Hengstenberg, F; Mannela, RJ; et al. (1966) Mucociliary activity. Arch Environ Health  
24 12:460-466.  
25  
26 Bevan, DR; Ruggio, DM. (1991) Bioavailability *in vivo* of benzo[a]pyrene adsorbed to diesel particulate. Toxicol  
27 Ind Health 7:125-139.  
28  
29 Bohning, DE; Cohn, SH; Lee, HD; et al. (1980) Two-phase deep-lung clearance in man. In: Pulmonary toxicology  
30 of respirable particles: proceedings of the nineteenth annual Hanford life sciences symposium; October 1979;  
31 Richland, WA. Sanders, CL; Cross, FT; Dagle, GE; et al., eds. Washington, DC: U.S. Department of Energy; pp.  
32 149-161. Available from: NTIS, Springfield, VA; CONF-791002.  
33  
34 Bohning, DE; Atkins, HL; Cohn, SH. (1982) Long-term particle clearance in man: normal and impaired. In:  
35 Inhaled particles V: proceedings of an international symposium; September 1980; Cardiff, Wales. Walton, WH, ed.  
36 Ann Occup Hyg 26:259-271.  
37  
38 Bond, JA; Mitchell, CE; Li, AP. (1983) Metabolism and macromolecular covalent binding of benzo[a]pyrene in  
39 cultured Fischer-344 rat lung type II epithelial cells. Biochem Pharmacol 32:3771-3776.  
40  
41 Bond, JA; Sun, JD; Medinsky, MA; et al. (1986) Deposition, metabolism, and excretion of 1-[<sup>14</sup>C]nitropyrene and  
42 1-[<sup>14</sup>C]nitropyrene coated on diesel exhaust particles as influenced by exposure concentration. Toxicol Appl  
43 Pharmacol 85:102-117.  
44  
45 Bond, JA; Johnson, NF; Snipes, MB; et al. (1990) DNA adduct formation in rat alveolar type II cells: cells  
46 potentially at risk for inhaled diesel exhaust. Environ Mol Mutagen 16:64-69.  
47  
48 Brain, JD; Mensah, GA. (1983) Comparative toxicology of the respiratory tract. Am Rev Respir Dis 128:S87-S90.  
49  
50 Brooks, AL; Wolff, RK; Royer, RE; et al. (1981) Deposition and biological availability of diesel particles and their  
51 associated mutagenic chemicals. Environ Int 5:263-267.  
52  
53 Campbell, RM; Lee, ML. (1984) Capillary column gas chromatographic determination of nitro polycyclic  
54 aromatic compounds in particulate extracts. Anal Chem 56:1026-1030.

1 Chan, TL; Lee, PS; Hering, WE. (1981) Deposition and clearance of inhaled diesel exhaust particles in the  
2 respiratory tract of Fischer rats. *J Appl Toxicol* 1:77-82.  
3

4 Chan, TL; Lee, PS; Hering, WE. (1984) Pulmonary retention of inhaled diesel particles after prolonged exposures  
5 to diesel exhaust. *Fundam Appl Toxicol* 4:624-631.  
6

7 Cohen, D; Arai, SF; Brain, JD. (1979) Smoking impairs long-term dust clearance from the lung. *Science*  
8 (Washington, DC) 204:514-517.  
9

10 Cohen, BS; Xiong, JQ; Fang, CP; et al. (1998) Deposition of charged particles on lung airways. *Health Phys*  
11 74:554-560.  
12

13 Crapo, JD; Young, SL; Fram, EK; et al. (1983) Morphometric characteristics of cells in the alveolar region of  
14 mammalian lungs. *Am Rev Respir Dis* 128:S42-S46.  
15

16 Cuddihy, RG; Yeh, HC. (1986) Model analysis of respiratory tract clearance of particles inhaled by people. In:  
17 Annual report of the Inhalation Toxicology Research Institute. Muggenburg, BA; Sun, JD, eds. Albuquerque, NM:  
18 Lovelace Biomedical and Environmental Research Institute; report no. LMF-115; pp. 140-147.  
19

20 Evans, MJ; Shami, SG; Martinez, LA. (1986) Enhanced proliferation of pulmonary alveolar macrophages after  
21 carbon instillation in mice depleted of blood monocytes by Strontium-89. *Lab Invest* 54:154-159.  
22

23 Felicetti, SA; Wolff, RK; Muggenburg, BA. (1981) Comparison of tracheal mucous transport in rats, guinea pigs,  
24 rabbits, and dogs. *J Appl Physiol: Respir Environ Exercise Physiol* 51:1612-1617.  
25

26 Ferin, J. (1982) Pulmonary alveolar pores and alveolar macrophage-mediated particle clearance. *Anat Rec*  
27 203:265-272.  
28

29 Ferin, J; Feldstein, ML. (1978) Pulmonary clearance and hilar lymph node content in rats after particle exposure.  
30 *Environ Res* 16:342-352.  
31

32 Freedman, AP; Robinson, SE. (1988) Noninvasive magnetopneumographic studies of lung dust retention and  
33 clearance in coal miners. In: *Respirable dust in the mineral industries: health effects, characterization, and control:*  
34 *proceedings of the international symposium on respirable dust in the mineral industries; October 1986; University*  
35 *Park, PA. Frantz, RL; Ramani, RV, eds. University Park, PA: Pennsylvania State University Press; pp. 181-186.*  
36

37 Freijer, JI; Cassee, FR; Subramaniam, R; et al. (1999) Multiple path particle deposition model developed by the  
38 Chemical Industry Institute of Toxicology (CIIT) and the Rijksinstituut Voor Volksgezondheid en Milieu (RIVM),  
39 RIVM Publication No. 65001019.  
40

41 Frey, JW; Corn, M. (1967) Physical and chemical characteristics of particulates in a diesel exhaust. *Am Ind Hyg*  
42 *Assoc J* 28:468-478.  
43

44 George, G; Hook, GER. (1984) The pulmonary extracellular lining. *Environ Health Perspect* 55:227-237.  
45

46 Gerde, P; Medinsky, MA; Bond, JA. (1991a) Particle-associated polycyclic aromatic hydrocarbons - a reappraisal  
47 of their possible role in pulmonary carcinogenesis. *Toxicol Appl Pharmacol* 108:1-13.  
48

49 Gerde, P; Medinsky, MA; Bond, JA. (1991b) The retention of polycyclic aromatic hydrocarbons in the bronchial  
50 airways and in the alveolar region - a theoretical comparison. *Toxicol Appl Pharmacol* 107:239-252.  
51

52 Gerde, P; Muggenberg, BA; Dahl, AR. (1999) Bioavailability, absorption and metabolism of diesel soot-absorbed  
53 benzo(a)pyrene after single-breath exposures in dogs. In: *Relationships between acute and chronic effects of air*  
54 *pollution: 7th international inhalation symposium; February; Hannover, Federal Republic of Germany; p. 76.*

1 Gibb, FR; Morrow, PE. (1962) Alveolar clearance in dogs after inhalation of an iron 59 oxide aerosol. *J Appl*  
2 *Physiol* 17:429-432.  
3  
4 Godleski, JJ; Stearns, RC; Katler, MR; et al. (1988) Particle dissolution in alveolar macrophages assessed by  
5 electron energy loss analysis using the Zeiss CEM902 electron microscope. *J Aerosol Med* 1:198-199.  
6  
7 Griffis, LC; Wolff, RK; Henderson, RF; et al. (1983) Clearance of diesel soot particles from rat lung after a  
8 subchronic diesel exhaust exposure. *Fundam Appl Toxicol* 3:99-103.  
9  
10 Gurley, LR; Spall, WD; Valdez, JG; et al. (1988) An HPLC procedure for the analysis of proteins in lung lavage  
11 fluid. *Anal Biochem* 172:465-478.  
12  
13 Harmsen, AG; Muggenburg, BA; Snipes, MB; et al. (1985) The role of macrophages in particle translocation from  
14 lungs to lymph nodes. *Science (Washington, DC)* 230:1277-1280.  
15  
16 Health Effects Institute. (1995) Diesel exhaust: a critical analysis of emissions, exposure, and health effects: a  
17 special report of the Institute's Diesel Working Group. Cambridge, MA: Health Effects Institute.  
18  
19 Heinrich, U; Muhle, H; Takenaka, S; et al. (1986) Chronic effects on the respiratory tract of hamsters, mice, and  
20 rats after long-term inhalation of high concentrations of filtered and unfiltered diesel engine emissions. *J Appl*  
21 *Toxicol* 6:383-395.  
22  
23 Hemminki, K; Söderling, J; Ericson, P; et al. (1994) DNA adducts among personnel servicing and loading diesel  
24 vehicles. *Carcinogenesis* 15:767-769.  
25  
26 Heppleston, AG. (1961) Observations on the disposal of inhaled dust by means of the double exposure technique.  
27 In: *Inhaled particles and vapours: proceedings of an international symposium; March-April 1960; Oxford, United*  
28 *Kingdom*. Davies, CN, ed. New York: Pergamon Press; pp. 320-326.  
29  
30 Heppleston, AG; Young, AE. (1973) Uptake of inert particulate matter by alveolar cells: an ultrastructural study. *J*  
31 *Pathol* 111:159-164.  
32  
33 Heyder, J; Gebhart, J; Rudolf, G; et al. (1986) Deposition of particles in the human respiratory tract in the size  
34 range 0.005-15  $\mu\text{m}$ . *J Aerosol Sci* 17:811-825.  
35  
36 Hiura, TS; Kaxzubowski, MP; Li, N; et al. (1999) Chemicals in diesel exhaust particles generate oxygen radicals  
37 and induce apoptosis in macrophages. *J Immunol* 163:5582-5591.  
38  
39 Holt, PF. (1981) Transport of inhaled dust to extrapulmonary sites. *J Pathol* 133:123-129.  
40  
41 International Commission on Radiological Protection (ICRP). (1979) Limits for intakes of radionuclides by  
42 workers. Oxford, United Kingdom: Pergamon Press; ICRP publication 30, part 1.  
43  
44 ICRP. (1994) Human respiratory tract model for radiological protection: a report of a task group of the  
45 International Commission on Radiological Protection. Oxford, United Kingdom: Elsevier Science Ltd. (ICRP  
46 publication 66; *Annals of the ICRP*: v. 24, nos. 1-3).  
47  
48 International Life Sciences Institute (ILSI). (2000) ILSI Risk Science Institute Workshop: the relevance of the rat  
49 lung response to particle overload for human risk assessment. Gardner, DE, ed. *Inhal Toxicol* 12(1-2):1-148.  
50  
51 Jammet, H; Drutel, P; Parrot, R; et al. (1978) Étude de l'épuration pulmonaire chez l'homme après administration  
52 d'aérosols de particules radioactives [Study of pulmonary function in man after administration of radioactive  
53 particulate aerosols]. *Radioprotection* 13:143-166.  
54

- 1 Keane, MJ; Xing, S-G; Harrison JC; et al. (1991) Genotoxicity of diesel-exhaust particles dispersed in simulated  
2 pulmonary surfactant. *Mutat Res* 260:233-238.  
3
- 4 King, LC; Kohan, MJ; Austin, AC; et al. (1981) Evaluation of the release of mutagens from diesel particles in the  
5 presence of physiological fluids. *Environ Mutagen* 3:109-121.  
6
- 7 Kittelson, DB; Dolan, DF; Verrant, JA. (1978) Investigation of a diesel exhaust aerosol. Warrendale, PA: Society  
8 of Automotive Engineers, Inc.; technical paper series no. 78109.  
9
- 10 Kuempel, ED. (2000). Comparison of human and rodent lung dosimetry models for particle clearance and  
11 retention. *Drug Chem Toxicol* 23(1):203-222.  
12
- 13 Lee, PS; Chan, TL; Hering, WE. (1983) Long-term clearance of inhaled diesel exhaust particles in rodents. *J*  
14 *Toxicol Environ Health* 12:801-813.  
15
- 16 Lee, KP; Trochimowicz, HJ; Reinhardt, CF. (1985) Transmigration of titanium dioxide (TiO<sub>2</sub>) particles in rats  
17 after inhalation exposure. *Exp Mol Pathol* 42:331-343.  
18
- 19 Lee, KP; Henry, NW, III; Trochimowicz, HJ.; et al. (1986) Pulmonary response to impaired lung clearance in rats  
20 following excessive TiO<sub>2</sub> dust deposition. *Environ Res* 41:144-167.  
21
- 22 Lee, KP; Ulrich, CE; Geil, RG; et al. (1988) Effects of inhaled chromium dioxide dust on rats exposed for two  
23 years. *Fundam Appl Toxicol* 10:125-145.  
24
- 25 Lehnert, BE. (1988) Distributions of particles in alveolar macrophages during lung clearance. *J Aerosol Med*  
26 1:206-207.  
27
- 28 Lehnert, BE. (1989) Rates of disappearance of alveolar macrophages during lung clearance as a function of  
29 phagocytized particulate burden [abstract]. *Am Rev Respir Dis* 139(suppl.):A161.  
30
- 31 Lehnert, BE. (1990) Alveolar macrophages in a particle "overload" condition. *J Aerosol Med* 3(suppl. 1):S9-S30.  
32
- 33 Lehnert, BE; Morrow, PE. (1985) Association of <sup>59</sup>iron oxide with alveolar macrophages during alveolar clearance.  
34 *Exp Lung Res* 9:1-16.  
35
- 36 Lehnert, BE; Valdez, YE; Bomalaski, SH. (1988) Analyses of particles in the lung free cell, tracheobronchial  
37 lymph nodal, and pleural space compartments following their deposition in the lung as related to lung clearance  
38 mechanisms. In: *Inhaled particles VI: proceedings of an international symposium and workshop on lung*  
39 *dosimetry; September 1985; Cambridge, United Kingdom.* Dodgson, J; McCallum, RI; Bailey, MR; et al., eds. *Ann*  
40 *Occup Hyg* 32 (suppl. 1):125-140.  
41
- 42 Lehnert, BE; Cline, A; London, JE. (1989) Kinetics of appearance of polymorphonuclear leukocytes and their  
43 particle burdens during the alveolar clearance of a high lung burden of particles. *Toxicologist* 9:77.  
44
- 45 Leung, HW; Henderson, RF; Bond, JA; et al. (1988) Studies on the ability of rat lung and liver microsomes to  
46 facilitate transfer and metabolism of benzo[a]pyrene from diesel particles. *Toxicology* 51:1-9.  
47
- 48 Lippmann, M; Schlesinger, RB. (1984) Interspecies comparisons of particle deposition and mucociliary clearance  
49 in tracheobronchial airways. *J Toxicol Environ Health* 13:441-469.  
50
- 51 Lundborg, M; Lind, B; Camner, P. (1984) Ability of rabbit alveolar macrophages to dissolve metals. *Exp Lung Res*  
52 7:11-22.  
53

- 1 Marafante, E; Lundborg, M; Vahter, M; et al. (1987) Dissolution of two arsenic compounds by rabbit alveolar  
2 macrophages *in vitro*. *Fundam Appl Toxicol* 8:382-388.  
3
- 4 Mauderly, JL. (1996) Lung overload: the dilemma and opportunities for resolution. In: Particle overload in the rat  
5 lung and lung cancer: implications for human risk assessment. Proceedings of a conference; March 1995;  
6 Cambridge, MA. Mauderly, JL; McCunney, RJ; eds. New York: Taylor & Francis.  
7
- 8 McClellan, RO; Brooks, AL; Cuddihy, RG; et al. (1982) Inhalation toxicology of diesel exhaust particles. In:  
9 Toxicological effects of emissions from diesel engines: proceedings of the EPA diesel emissions symposium;  
10 October 1981; Raleigh, NC. Lewtas, J, ed. New York: Elsevier Biomedical; pp. 99-120. (Developments in  
11 toxicology and environmental science: v. 10).  
12
- 13 Morrow, PE. (1966) International Commission on Radiological Protection (ICRP) task group on lung dynamics,  
14 deposition and retention models for internal dosimetry of the human respiratory tract. *Health Phys* 12:173.  
15
- 16 Morrow, PE. (1988) Possible mechanisms to explain dust overloading of the lungs. *Fundam Appl Toxicol*  
17 10:369-384.  
18
- 19 Morrow, PE. (1994) Mechanisms and significance of "particle overload." In: Toxic and carcinogenic effects of  
20 solid particles in the respiratory tract: [proceedings of the 4th international inhalation symposium]; March 1993;  
21 Hannover, Germany. Mohr, U; Dungworth, DL; Mauderly, JL; et al., eds. Washington, DC: International Life  
22 Sciences Institute Press; pp. 17-25.  
23
- 24 Morrow, PE; Yu, CP. (1993) Models of aerosol behavior in airways and alveoli. In: Aerosols in medicine:  
25 principles, diagnosis and therapy. 2nd rev. ed. Moren, F; Dolovich, MB; Newhouse, MT; et al., eds. Amsterdam:  
26 Elsevier; pp. 157-193.  
27
- 28 Muhle, H; Bellman, B; Creutzenberg, O; et al. (1990) Dust overloading of lungs after exposure of rats to particles  
29 of low solubility: comparative studies. *J Aerosol Sci* 21:374-377.  
30
- 31 National Research Council (NRC). (1995) Science and judgment in risk assessment. Washington, DC: National  
32 Research Council.  
33
- 34 Nielsen, PS; Andreassen, A; Farmer, PB; et al. (1996) Biomonitoring of diesel exhaust-exposed workers. DNA and  
35 hemoglobin adducts and urinary 1-hydroxypyrene as markers of exposure. *Toxicol Lett* 86:27-37.  
36
- 37 Nikula, KJ; Avila, KJ; Griffith, WC; et al. (1997a) Sites of particle retention and lung tissue responses to  
38 chronically inhaled diesel exhaust and coal dust in rats and cynomolgus monkeys. In: Proceedings of the sixth  
39 international meeting on the toxicology of natural and man-made fibrous and non-fibrous particles; September  
40 1996; Lake Placid, NY. Driscoll, KE; Oberdörster, G, eds. *Environ Health Perspect Suppl* 105(5):1231-1234.  
41
- 42 Nikula, KJ; Avila, KJ; Griffith, WC; et al. (1997b) Lung tissue responses and sites of particle retention differ  
43 between rats and cynomolgus monkeys exposed chronically to diesel exhaust and coal dust. *Fundam Appl Toxicol*  
44 37:37-53.  
45
- 46 Nilsen, A; Nyberg, K; Camner, P. (1988) Intraphagosomal pH in alveolar macrophages after phagocytosis *in vivo*  
47 and *in vitro* of fluorescein-labeled yeast particles. *Exp Lung Res* 14:197-207.  
48
- 49 Oberdörster, G. (1988) Lung clearance of inhaled insoluble and soluble particles. *J Aerosol Med* 1:289-330.  
50
- 51 Oberdörster, G; Ferin, J; Morrow, PE. (1992) Volumetric loading of alveolar macrophages (AM): a possible basis  
52 for diminished AM-mediated particle clearance. *Exp Lung Res* 18:87-104.  
53

- 1 Ohkuma, S; Poole, B. (1978) Fluorescence probe measurement of the intralysosomal pH in living cells and the  
2 perturbation of pH by various agents. *Proc Nat. Acad Sci U S A* 75:3327-3331.  
3
- 4 Österholm, AM; Fält, S; Lambert, B; et al. (1995) Classification of mutations at the human hprt-locus in  
5 T-lymphocytes of bus maintenance workers by multiplex-PCR and reverse transcriptase-PCR analysis.  
6 *Carcinogenesis* 16:1909-1995.  
7
- 8 Pepelko, WE. (1987) Feasibility of dose adjustment based on differences in long-term clearance rates of inhaled  
9 particulate matter in humans and laboratory animals. *Regul Toxicol Pharmacol* 7:236-252.  
10
- 11 Phalen, RF; Oldham, MJ. (1983) Tracheobronchial airway structure as revealed by casting techniques. *Am Rev*  
12 *Respir Dis* 128:S1-S4.  
13
- 14 Powdrill, J; Buckley, C; Valdez, YE; et al. (1989) Airway intra-luminal macrophages: origin and role in lung  
15 clearance. *Toxicologist* 9:77.  
16
- 17 Pritchard, JN. (1989) Dust overloading causes impairment of pulmonary clearance: evidence from rats and  
18 humans. *Exp Pathol* 37:39-42.  
19
- 20 Raabe, OG. (1982) Deposition and clearance of inhaled aerosols. In: *Mechanisms in respiratory toxicology*.  
21 Witschi, H, ed. Boca Raton, FL: CRC Press; pp. 27-76.  
22
- 23 Raabe, OG; Al-Bayati, MA; Teague, SV; et al. (1988) Regional deposition of inhaled monodisperse, coarse, and  
24 fine aerosol particles in small laboratory animals. In: *Inhaled particles VI: proceedings of an international*  
25 *symposium and workshop on lung dosimetry; September 1985; Cambridge, United Kingdom*. Dodgson, J;  
26 McCallum, RI; Bailey, MR; et al., eds. *Ann Occup Hyg* 32(suppl. 1):53-63.  
27
- 28 Riley, PA; Dean, RT. (1978) Phagocytosis of latex particles in relation to the cell cycle in 3T3 cells. *Exp Cell Biol*  
29 46:367-373.  
30
- 31 Robertson, B. (1980) Basic morphology of the pulmonary defence system. *Eur J Respir Dis* 61(suppl. 107):21-40.  
32
- 33 Sandusky, CB; Cowden, MW; Schwartz, SL. (1977) Effect of particle size on regurgitative exocytosis by rabbit  
34 alveolar macrophages. In: *Pulmonary macrophage and epithelial cells: proceedings of the sixteenth annual*  
35 *Hanford biology symposium; September 1976; Richland, WA*. Sanders, CL; Schneider, RP; Dagle, GE; et al., eds.  
36 Washington, DC: Energy Research and Development Administration; pp. 85-105. (ERDA symposium series: no.  
37 43). Available from: NTIS, Springfield, VA; CONF-760927.  
38
- 39 Schanker, LS; Mitchell, EW; Brown, RA, Jr. (1986) Species comparison of drug absorption from the lung after  
40 aerosol inhalation or intratracheal injection. *Drug Metab Dispos* 14:79-88.  
41
- 42 Schlesinger, RB. (1985) Comparative deposition of inhaled aerosols in experimental animals and humans: a  
43 review. *J Toxicol Environ Health* 15:197-214.  
44
- 45 Schlesinger, RB; Ben-Jebria, A; Dahl, AR; et al. (1997) Disposition of inhaled toxicants. In: *Handbook of human*  
46 *toxicology*. Massaro, EJ, ed. Boca Raton, FL: CRC Press; pp. 493-550.  
47
- 48 Schum, M; Yeh, HC. (1980) Theoretical evaluation of aerosol deposition in anatomical models of mammalian lung  
49 airways. *Bull Math Biol* 42:1-15.  
50
- 51 Siak, JS; Chan, TL; Lee, PS. (1980) Diesel particulate extracts in bacterial test systems. In: *Health effects of diesel*  
52 *engine emissions: proceedings of an international symposium, v. 1; December 1979; Cincinnati, OH*. Pepelko,  
53 WE; Danner, RM; Clarke, NA, eds. Cincinnati, OH: U.S. EPA, Health Effects Research Laboratory; pp. 245-262;  
54 EPA report no. EPA/600/9-80/057b. Available from: NTIS, Springfield, VA; PB81-173809.

- 1 Smith, TJ. (1985) Development and application of a model for estimating alveolar and interstitial dust levels. *Ann*  
2 *Occup Hyg* 29:495-516.
- 3
- 4 Snipes, MB. (1979) Long-term retention of monodisperse and polydisperse particles inhaled by beagle dogs, rats  
5 and mice. Albuquerque, NM: Lovelace Biomedical and Environmental Research Institute; *Inhalation Toxicology*  
6 *Research Institute annual report LF-69*; pp. 420-423.
- 7
- 8 Snipes, MB; Clem, MF. (1981) Retention of microspheres in the rat lung after intratracheal instillation. *Environ*  
9 *Res* 24:33-41.
- 10
- 11 Snipes, MB; Olson, TR; Yeh, HC. (1988) Deposition and retention patterns for 3-, 9-, and 15- $\mu$ m latex  
12 microspheres inhaled by rats and guinea pigs. *Exp Lung Res* 14:37-50.
- 13
- 14 Snipes, MB; McClellan, RO; Mauderly, JL; et al. (1989) Retention patterns for inhaled particles in the lung:  
15 comparisons between laboratory animals and humans for chronic exposures. *Health Phys* 57(suppl. 1):69-78.
- 16
- 17 Sorokin, SP; Brain, JD. (1975) Pathways of clearance in mouse lungs exposed to iron oxide aerosols. *Anat Rec*  
18 181:581-625.
- 19
- 20 Stahlhofen, W; Gebhart, J; Heyder, J. (1980) Experimental determination of the regional deposition of aerosol  
21 particles in the human respiratory tract. *Am Ind Hyg Assoc J* 41:385-398a.
- 22
- 23 Stahlhofen, W; Koebrich, R; Rudolf, G; et al. (1990) Short-term and long-term clearance of particles from the  
24 upper human respiratory tract as function of particle size. *J Aerosol Sci* 21(suppl. 1):S407-S410.
- 25
- 26 Stöber, W; Einbrodt, HJ; Klosterkötter, W. (1967) Quantitative studies of dust retention in animal and human  
27 lungs after chronic inhalation. In: *Inhaled particles and vapours II: proceedings of an international*  
28 *symposium; September-October 1965; Cambridge, United Kingdom*. Davies, CN, ed. Oxford, United Kingdom:  
29 Pergamon Press; pp. 409-418.
- 30
- 31 Stöber, W; Morrow, PE; Hoover, MD. (1989) Compartmental modeling of the long-term retention of insoluble  
32 particles deposited in the alveolar region of the lung. *Fundam Appl Toxicol* 13:823-842.
- 33
- 34 Stöber, W; McClellan, RO; Morrow, PE. (1993) Approaches to modeling disposition of inhaled particles and fibers  
35 in the lung. In: *Toxicology of the lung*. Gardner, DE; Crapo, JD; McClellan, RO, eds. New York: Raven Press; pp.  
36 527-601.
- 37
- 38 Stöber, W; Morrow, PE; Koch, W; et al. (1994) Alveolar clearance and retention of inhaled insoluble particles in  
39 rats simulated by a model inferring macrophage particle load distributions. *J Aerosol Sci* 25:975-1002.
- 40
- 41 Strom, KA. (1984) Response of pulmonary cellular defenses to the inhalation of high concentrations of diesel  
42 exhaust. *J Toxicol Environ Health* 13:919-944.
- 43
- 44 Strom, KA; Chan, TL; Johnson, JT. (1988) Pulmonary retention of inhaled submicron particles in rats: diesel  
45 exhaust exposures and lung retention model. In: *Inhaled particles VI: proceedings of an international symposium*  
46 *and workshop on lung dosimetry; September 1985; Cambridge, United Kingdom*. Dodgson, J; McCallum, RI;  
47 Bailey, MR; et al., eds. *Ann Occup Hyg* 32(suppl. 1):645-657.
- 48
- 49 Subramaniam, RP; Miller, FJ; Asgarian, B. (1998) Numerical predictions of regional deposition of fine particles in  
50 the human lung using a multiple-path model. *Proceedings of the American Association of Aerosol Research,*  
51 *annual meeting; Denver, CO*.
- 52
- 53 Sun, JD; Wolff, RK; Kanapilly, GM. (1982) Deposition, retention, and biological fate of inhaled benzo(a)pyrene  
54 adsorbed onto ultrafine particles and as a pure aerosol. *Toxicol Appl Pharmacol* 65:231-244.

1 Sun, JD; Wolff, RK; Kanapilly, GM; et al. (1984) Lung retention and metabolic fate of inhaled benzo(a)pyrene  
2 associated with diesel exhaust particles. *Toxicol Appl Pharmacol* 73:48-59.  
3  
4 Tong, HY; Karasek, FW. (1984) Quantitation of polycyclic aromatic hydrocarbons in diesel exhaust particulate  
5 matter by high-performance liquid chromatography fractionation and high-resolution gas chromatography. *Anal*  
6 *Chem* 56:2129-2134.  
7  
8 U.S. Environmental Protection Agency (U.S. EPA). (1982) Air quality criteria for particulate matter and sulfur  
9 oxides. Research Triangle Park, NC: Office of Health and Environmental Assessment, Environmental Criteria and  
10 Assessment Office; EPA report no. EPA/600/8-82-029aF-cF. 3v. Available from: NTIS, Springfield, VA;  
11 PB84-156777.  
12  
13 U.S. EPA. (1993) Provisional guidance for quantitative risk assessment of polycyclic aromatic hydrocarbons.  
14 Office of Health and Environmental Assessment; EPA report no. EPA/600/R-93/089.  
15  
16 U.S. EPA. (1996) Air quality criteria for particulate matter. Research Triangle Park, NC: National Center for  
17 Environmental Assessment-RTP Office; report nos. EPA/600/P-95/001aF-cF. 3v. Available from: NTIS,  
18 Springfield, VA; PB96-168224.  
19  
20 Valberg, PA; Watson, AY. (1999). Comparative mutagenic dose of ambient diesel engine exhaust. *Inhal Toxicol*  
21 11(3):215-228.  
22  
23 Vastag, E; Matthys, H; Zsomboki, G; et al. (1986) Mucociliary clearance in smokers. *Eur J Respir Dis* 68:107-113.  
24  
25 Vostal, JJ; Schreck, RM; Lee, PS; et al. (1982) Deposition and clearance of diesel particles from the lung. In:  
26 Toxicological effects of emissions from diesel engines: proceedings of the 1981 EPA diesel emissions symposium;  
27 October 1981; Raleigh, NC. Lewtas, J, ed. New York: Elsevier Biomedical; pp. 143-159. (Developments in  
28 toxicology and environmental science: v. 10).  
29  
30 Waite, DA; Ramsden, D. (1971) The inhalation of insoluble iron oxide particles in the sub-micron range. Part I.  
31 Chromium-51 labelled aerosols. Winfrith, Dorchester, Dorset, United Kingdom: Atomic Energy Establishment;  
32 report no. AEEW-R740.  
33  
34 Warheit, DB; Overby, LH; George, G; et al. (1988) Pulmonary macrophages are attracted to inhaled particles  
35 through complement activation. *Exp Lung Res* 14:51-66.  
36  
37 Weibel, ER. (1963) Morphometry of the human lung. New York: Academic Press, Inc.  
38  
39 White, HJ; Garg, BD. (1981) Early pulmonary response of the rat lung to inhalation of high concentration of diesel  
40 particles. *J Appl Toxicol* 1:104-110.  
41  
42 Wolff, RK; Gray, RL. (1980) Tracheal clearance of particles. In: Inhalation Toxicology Research Institute annual  
43 report: 1979-1980. Diel, JH; Bice, DE; Martinez, BS, eds. Albuquerque, NM: Lovelace Biomedical and  
44 Environmental Research Institute; p. 252; report no. LMF-84.  
45  
46 Wolff, RK; Henderson, RF; Snipes, MB; et al. (1986) Lung retention of diesel soot and associated organic  
47 compounds. In: Carcinogenic and mutagenic effects of diesel engine exhaust: proceedings of the international  
48 satellite symposium on toxicological effects of emissions from diesel engines; July; Tsukuba Science City, Japan.  
49 Ishinishi, N; Koizumi, A; McClellan, R; et al. eds. Amsterdam: Elsevier Science Publishers BV.; pp. 199-211.  
50 (Developments in toxicology and environmental science: v. 13).  
51  
52 Wolff, RK; Henderson, RF; Snipes, MB; et al. (1987) Alterations in particle accumulation and clearance in lungs  
53 of rats chronically exposed to diesel exhaust. *Fundam Appl Toxicol* 9:154-166.  
54

1 World Health Organization. (1996) Diesel fuel and exhaust emissions. Geneva, Switzerland: World Health  
2 Organization, International Programme on Chemical Safety. (Environmental health criteria 171).  
3  
4 Wright, JR; Clements, JA. (1987) Metabolism and turnover of lung surfactant. *Am Rev Respir Dis* 136:426-444.  
5  
6 Xu, GB; Yu, CP. (1987) Deposition of diesel exhaust particles in mammalian lungs: a comparison between rodents  
7 and man. *Aerosol Sci Technol* 7:117-123.  
8  
9 Yeh, HC; Schum, GM. (1980) Models of human lung airways and their application to inhaled particle deposition.  
10 *Bull Math Biol* 42:461-480.  
11  
12 Yu, CP. (1978) Exact analysis of aerosol deposition during steady breathing. *Powder Technol* 21:55-62.  
13  
14 Yu, CP; Diu, CK. (1983) Total and regional deposition of inhaled aerosols in humans. *J Aerosol Sci* 5:599-609.  
15  
16 Yu, CP; Xu, GB. (1986) Predictive models for deposition of diesel exhaust particulates in human and rat lungs.  
17 *Aerosol Sci Technol* 5:337-347.  
18  
19 Yu, CP; Yoon, KJ. (1990) Retention modeling of diesel exhaust particles in rats and humans. Amherst, NY: State  
20 University of New York at Buffalo (Health Effects Institute research report no. 40).  
21  
22 Yu, CP; Chen, YK; Morrow, PE. (1989) An analysis of alveolar macrophage mobility kinetics at dust overloading  
23 of the lungs. *Fundam Appl Toxicol* 13:452-459.  
24  
25 Yu, CP; Yoon, KJ; Chen, YK. (1991) Retention modeling of diesel exhaust particles in rats and humans. *J Aerosol*  
26 *Med* 4(2):79-115.  
27  
28 Yu, CP; Ding, YJ; Zhang, L; et al. (1996) A clearance model of refractory ceramic fibers in the rat lung including  
29 fiber dissolution and breakage. *J Aerosol Sci* 27:151-160.